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LINE-1 retrotransposition is tightly restricted by
layers of regulatory control, with epigenetic path-
ways being the best characterized. Looking at
post-transcriptional regulation, we now show that
LINE-1 mRNA 30 ends are pervasively uridylated in
various human cellular models and in mouse testes.
TUT4 and TUT7 uridyltransferases catalyze themodi-
fication and function in cooperation with the heli-
case/RNPase MOV10 to counteract the RNA chap-
erone activity of the L1-ORF1p retrotransposon
protein. Uridylation potently restricts LINE-1 retro-
transposition by a multilayer mechanism depending
on differential subcellular localization of the uridyl-
transferases. We propose that uridine residues
added by TUT7 in the cytoplasm inhibit initiation of
reverse transcription of LINE-1 mRNAs once they
are reimported to the nucleus, whereas uridylation
by TUT4, which is enriched in cytoplasmic foci, de-
stabilizes mRNAs. These results provide a model
for the post-transcriptional restriction of LINE-1,
revealing a key physiological role for TUT4/7-medi-
ated uridylation in maintaining genome stability.
INTRODUCTION
Long interspersed element-1 (LINE-1, thereafter L1) is a group of
active non-long-terminal repeat retrotransposons. Through their
ability to mobilize and insert into new genomic locations via a
copy-and-pastemechanism, L1s have acted as amajor dynamic
force that shaped the genomes of humans, mice, and other
vertebrate species (Cordaux and Batzer, 2009; Faulkner and
Garcia-Perez, 2017). Roughly 500,000 L1 copies constitute
17% of the human genome. Because of 50 truncations, rear-
rangements, and mutations, most L1s can no longer mobilize.Cell 175, 1537–1548, Septem
This is an open access article under the CC BY-NHowever, in an average human genome 80–100 L1 copies
remain potentially active with just <10 highly active L1 copies
accounting for genetic variation and mosaicism in humans (re-
viewed in Beck et al. [2011]; Hancks and Kazazian [2012]).
Active L1 elements are 6–7 kb in length and contain: a 50
UTR, two open reading frames (ORFs) separated by a short linker
sequence, and a short 30 UTR. The 50 UTR contains an internal
RNA polymerase II promoter (Swergold, 1990) that drives tran-
scription of the bicistronic L1mRNAwhich is translated by an un-
conventional mechanism into L1-ORF1p and L1-ORF2p (Alisch
et al., 2006; Dmitriev et al., 2007). L1-ORF1p is a 40 kDa nucleic
acid chaperone which, upon translation, forms homotrimers and
tightly encapsulates its parental mRNA (Callahan et al., 2012;
Khazina et al., 2011; Martin et al., 2003; Naufer et al., 2016).
The 150 kDa L1-ORF2p functions as an endonuclease (Feng
et al., 1996) and reverse transcriptase (Mathias et al., 1991).
L1-ORF2p is translated far less efficiently than L1-ORF1p (Alisch
et al., 2006) and is thought to associate with the poly(A) tail of L1
mRNA (Doucet et al., 2015). L1-ORF2p, together with L1-mRNA
encapsulated by L1-ORF1p, forms a minimal retrotransposition
particle, or L1-RNP (Doucet et al., 2010; Kulpa and Moran,
2005). Once in the nucleus, L1-RNPs generate new L1 insertions
in the genome through a mechanism termed ‘‘target-primed
reverse transcription’’ (TPRT) (Jurka, 1997).
Many cellular pathways act to restrict retrotransposition
at transcriptional and post-transcriptional levels (reviewed in
Goodier [2016]; Pizarro and Cristofari [2016]; Yang and Wang
[2016]). However, the mechanism of the latter is not clear.
Even for the well-established retrotransposition and retrovirus
restriction factor, the RNA helicase MOV10 (Arjan-Odedra
et al., 2012; Choi et al., 2018; Goodier et al., 2012; Li et al.,
2013; Lu et al., 2012; Skariah et al., 2017), the exact mechanisms
of action remain to be clarified.
Here,weexamined30 uridylationofL1 retrotransposons. Theur-
idylation process involves addition of non-templated uridine resi-
dues to 30 ends of RNA by terminal uridyltransferases (TUTases).
In fact, cytoplasmic uridylation mediated by two multi-domain
TUTases, TUT4 and TUT7, is an abundant and importantber 6, 2018 ª 2018 The Author(s). Published by Elsevier Inc. 1537
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. TUT4 and TUT7 Restrict L1
Retrotransposition
(A) Flowchart of the plasmid-based L1 retro-
transposition assays that allow assessment of
retrotransposition events by either flow cytometry-
based monitoring of cellular EGFP fluorescence
(megfpI reporter) or counting drug-resistant col-
onies (mneoI reporter).
(B) Effects of overexpression of either WT or
mutant (MT) TUT4 or TUT7 or WT TUT1, MOV10,
or MBP (control) (each point = biological replicate)
on L1 retrotransposition in HEK293T cells.
Negative control (JM111): a retrotransposition-
defective reporter (L1-ORF1pR261A/R262A). The
results of independent experiments were normal-
ized relative to the control (MBP). Statistical sig-
nificance was calculated using one-way ANOVA
and Tukey’s multiple comparison test (***p <
0.001; **p < 0.01; and *p < 0.05, in comparison
to MBP).
(C) Retrotransposition assay in HEK293T cells
depleted of TUT7, TUT4 (alone or combined),
MOV10, or TUT1 using siRNAs. A control with
a non-targeting siRNA was included (CNTRL).
Normalization was done relative to CNTRL. Statistical analysis was performed like in (B) (comparison to CNTRL shown). There is no significant difference between
CNTRL and TUT1, and a comparison to TUT1 instead of CNTRL gives the same statistical significances.
(D) L1 retrotransposition assays in HeLa-HA cells using mneoI L1 retrotransposition reporter assay. The results were normalized, relative to the control non-
targeting siRNA (CNTRL). Statistical analysis is the same as that performed in (B). Shown are comparisons to CNTRL. Normalization was done to CNTRL.
Data in (B)–(D) are represented as medians with individual points and interquartile ranges. See also Figure S1.modification of 30 ends of a variety of cellular RNAs (reviewed in
qabno et al. [2016a]; Norbury [2013]) including histone mRNAs
(MullenandMarzluff, 2008;Schmidtetal., 2011), let-7pre-miRNAs
(Heo et al., 2012; Faehnle et al., 2017), mature miRNAs (Thornton
et al., 2014), canonicalmRNAs (Lim et al., 2014), andmultiple non-
coding RNAs (qabno et al., 2016b; Pirouz et al., 2016; Ustianenko
et al., 2016). Although monouridylation of pre-let7 is involved in
biogenesis of maturemiRNAs (Heo et al., 2012), in all other known
instances, uridylation is linked to RNA destabilization, with an
apparent role in apoptosis-inducing global mRNA decay (Thomas
et al., 2015). Another uridyltransferase in human cells is nuclear
TUT1, which is involved in the maturation of U6 small nuclear
RNA (snRNA) (Mroczek and Dziembowski, 2013).
Herein, we present a mechanism for L1 retrotransposition re-
striction. First, we demonstrate abundant uridylation of endoge-
nous L1 mRNAs in a variety of human cell types and mice testes
and show that uridylated L1mRNAs have severely compromised
retrotransposition, despite their apparent persistence in the cell
and lack of major effects of uridylation on L1-ORF1p and
L1-ORF2p abundance. Uridylation involves cooperation be-
tween MOV10 helicase and TUT4 and TUT7, as revealed by a
combination of in vivo and in vitro experiments. We speculate
that uridylation-dependent restriction occurs by the inhibition
of initiation of RT by L1-ORF2p during TPRT and, partially, by
enhanced L1 mRNA decay.
RESULTS
TUT4/7Restrict Retrotransposition of ActiveHumanL1s
New genomic insertions of L1 retrotransposons by TPRT rely
on the endonuclease and reverse transcriptase activities of1538 Cell 175, 1537–1548, September 6, 2018L1-ORF2p, which first nicks genomic DNA preferentially within
a 50-TTTT/AA consensus sequence, exposing an oligo dT stretch
that, after base pairing with the L1 RNA poly(A) tail, serves
as a primer for RT (Doucet et al., 2015; Jurka, 1997; Monot
et al., 2013).
We hypothesized that uridylation of L1 mRNA might interfere
with the base-pairing during TPRT, leading to reduction of L1
retrotransposition. We therefore tested the effect of all human
TUTases – cytoplasmic TUT4 and TUT7 and nuclear TUT1 on
human L1 retrotransposition, using a reporter assay in cultured
cells (Moran et al., 1996; Ostertag et al., 2000; reviewed in Ko-
pera et al. [2016]). In the assay, cells are transfected with a
plasmid encoding a retrotransposition-competent L1 element
tagged with a retrotransposition indicator cassette (EGFP or
neomycin antibiotic resistance) cloned in the antisense orienta-
tion in the 30 UTR of the L1 (Figure 1A).
We co-transfected HEK293T cells with an active human L1 re-
porter tagged with the megfpI cassette (Ostertag et al., 2000),
together with plasmids for overexpression of wild-type (WT)
TUT4, TUT7, TUT1, or TUT4 and TUT7 catalytically inactive mu-
tants. As controls, we used plasmids that overexpress MBP pro-
tein, a plasmid for overexpression of MOV10 (positive control for
retrotransposition restriction) and a mutant retrotransposition-
incompetent L1 (JM111) (Moran et al., 1996). L1 retrotransposi-
tion was assessed by flow cytometry. Notably, overexpression
of WT TUT4 and TUT7, but neither of their catalytic mutants or
WT TUT1, inhibited retrotransposition >5-fold (Figure 1B). As ex-
pected, L1 retrotransposition was reduced by MOV10 overex-
pression and the mutant L1 construct failed to retrotranspose
(Figure 1B). Additional controls revealed that all co-transfected
factors were expressed at similar levels and did not elicit
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Figure 2. 30 RACE-Seq of L1 and Control
mRNAs
(A) Fraction of uridylated endogenous L1 mRNAs
in human embryonic carcinoma cells (PA-1), hu-
man embryonic stem cells (H9-hESCs), human
neuronal progenitor cells (derived from hESCs,
NPC) and in mouse testes (of P10 young mice; 4
mice, 8 testes).
(B) Distribution of 30 tails in endogenous L1
mRNAs. The tails were assigned to one of four
classes: U-tail (mono- and oligouridylated, but not
adenylated); AU-tail (adenylated and mono- and
oligouridylated); ‘‘no tail’’ (neither adenylated nor
uridylated, mostly truncated within the 30 UTR);
A-tail (oligo- and polyadenylated).
(C) Effect of siRNA-mediated depletion of MOV10
or TUT4 and TUT7 on uridylation of endogenous
L1 mRNAs in PA-1. Statistical significance was
calculated using one-way ANOVA and Tukey’s
multiple comparison test. The comparison and
significance are shown relative to a non-targeting
siRNA control (CNTRL, **p < 0.01).
(D) Uridylation of reporter L1 mRNAs in HEK293
cells under overexpression of MBP (CNTRL), WT,
and MT TUT7, TUT4, or MOV10 as indicated.
Statistical significance was calculated like in (C).
(E) Distribution of 30 tails in reporter L1 mRNAs,
visualized like in (B) under MBP, TUT4, TUT7, or
MOV10 overexpression conditions as indicated.
White-dashed line and black-dashed line indicate
control sample levels of uridylated (U+AU-tails)
and adenylated L1 mRNAs, respectively.
(F) Effects of overexpression of TUT1 and TENT5C
onuridylationof reporterL1mRNAs inHEK293cells.
Statistical significance was calculated like in (C).
(G) Effects of depleting TUT4, TUT7, or both TUTases using siRNAs in HEK293 cells on uridylation of reporter L1 mRNAs. Statistical significance was calculated
like in (C).
(H) Distribution of 30 tails in reporter L1 mRNAs, visualized like in (B) under TUT4, TUT4, and TUT7 or TUT7 depletion conditions in HEK293 cells as indicated.
(I) Distribution of endogenous L1 and control mRNAs’ (ACTB, GAPDH, and SOGA2) 30 ends in the cytoplasmic and nuclear compartments of PA-1 cells. The
numbers of sequenced 30 RACE reads are indicated and plotted assuming cyto+nuc = 100%. Qualities of the mRNAs’ 30 ends are color-coded like in (B).
Data in (A), (C), (D), (F), and (G) are medians with individual points and interquartile ranges shown. See also Figures S2 and S7 and Tables S1 and S2.cytotoxicity (Figures S1A, left panel, and S1B). Furthermore, we
tested other known human TENTs (terminal nucleotidyltrans-
ferases) including TENT2, TENT4B, and TENT5C, a member of
a novel TENT family and a terminal polyadenylase (Mroczek
et al., 2017). Neither of these enzymes significantly reduced L1
retrotransposition (Figures S1A and S1C).
To validate these results, in a reciprocal experiment, we co-
transfected L1 reporter with small interfering RNAs (siRNAs)
targeting TUT4 and TUT7 or MOV10. Accordingly, silencing
of TUTases increased retrotransposition by 2.2-fold relative
to the controls (non-targeting siRNAs) (Figures 1C, S1D, and
S1E). However, when only TUT4 or TUT7 was depleted, we
observed a stronger effect for TUT7 (2-fold) than for TUT4
(1.5-fold). Silencing of TUT1 had no effect (Figures 1CandS1F).
Finally, we used a different cell line (HeLa-HA) and a mneoI
retrotransposition indicator cassette, which, upon retrotranspo-
sition, confers resistance to G418 (Moran et al., 1996). Retro-
transposition frequency was then estimated by the number of
G418-resistant colonies (Figure 1A). Depletion of TUT7, TUT4,
or MOV10 resulted in a significant increase in the number of
G418-resistant foci (Figures 1D and S1G).Taken together, we show that TUT4 and TUT7 strongly reduce
L1 retrotransposition to levels similar to those observed with
MOV10. On the contrary, TUT1 and other human TENTs do not
affect L1 retrotransposition.
L1 mRNAs Are Uridylated
To uncover the molecular foundation of the observed L1 retro-
transposition restriction by TUT4 and TUT7, we investigated 30
ends of endogenous and reporter L1 mRNAs, using 30 RACE-
seq with individual transcript barcoding and TAIL-seq bioinfor-
matics pipeline (Chang et al., 2014) (Figure S7; Table S1).
We first investigated endogenous L1 mRNAs in a panel of hu-
man cells and in testes of P10 mice in which L1s are naturally
overexpressed (Branciforte and Martin, 1994; Coufal et al.,
2009; Garcia-Perez et al., 2010; Muotri et al., 2005). Remarkably,
30%–50% of all L1 mRNAs were uridylated (Figures 2A and
2B). Furthermore, a significant fraction of L1 mRNAs did not
possess poly(A) tails, and were instead truncated within their 30
UTRs, while 10%–25%of those non-poly(A) were oligouridylated
(Figure 2B, U-tail). Our data reveal that endogenous L1 mRNAs
contained mostly only short (uridylated) oligoadenine tails ofCell 175, 1537–1548, September 6, 2018 1539
15 adenines (As) and 3 uridines (Us) (Figure S2A; Table S2).
Using human embryonic carcinoma cells (PA-1) we showed
that the combined depletion of TUT4 and TUT7 significantly low-
ered the fraction of uridylated L1 mRNAs, with a concomitant in-
crease in the adenylated fraction (Figures 2C and S2B). This was
also visible for some control mRNAs including ACTB, GAPDH,
PABPC4, and SOGA2 (Figures S2A and S2C).
Next, we investigated the uridylation status of reporter L1
mRNAs in HEK293 cells. Notably, only 50% of the L1 reporter
transcripts had adenylated 30 ends. Moreover, we observed a
statistically significant increase in uridylation of L1 reporter
mRNAs in TUT7 WT, TUT4 WT, and MOV10-overexpressing
cells in comparison to the controls: MBP and the catalytic mu-
tants of TUT7 and TUT4 (Figure 2D). The increase in uridylation
was accompanied by a decrease in adenylation of L1 reporter
mRNAs (Figure 2E). Most of the uridylated L1 reporter 30 ends
contained on average 2.5 Us in controls and 3.5 Us in
TUT4, TUT7, and MOV10 overexpression, although >10 Us oli-
gouridine tails were also present (Figures S2D and S2E). When
TUT1 and TENT5Cwere overexpressed, we observed a non-sig-
nificant increase in L1 reporter uridylation (Figure 2F). To further
test whether uridylation under TUT4, TUT7, or MOV10 overex-
pression is specific to L1 mRNA or general, we performed 30
RACE-seq of mRNAs: ACTB, GAPDH, PABPC4, and SOGA2
(the latter two reported as highly uridylatedmRNAs in HeLa cells;
Chang et al., 2014). We did not observe effects on uridylation of
these mRNAs (Figure S2F), thus demonstrating that under our
experimental conditions L1 reporter mRNAs were preferentially
uridylated. We then tested effects of TUT4, TUT7, and TUT1
depletion on L1 reporter mRNA 30 ends. As expected, depletion
of both TUT4 and TUT7 resulted in a significant drop of L1 uridy-
lation and a concomitant increase in their adenylation (Figures
2G, 2H, and S2H). The same effects were observed for the four
control mRNAs (Figure S2G). Finally, consistent with the data
on endogenous L1 mRNAs, the depletion of TUT1 had no effect
(Figure S2I).
To retrotranspose, L1 RNPs must access the nucleus. Thus,
we performed 30 RACE-seq on RNAs isolated from the nucleus
and cytoplasm of PA-1 cells. In stark contrast to control mRNAs
(ACTB, GAPDH, and SOGA2), that were present mainly in the
cytoplasm, endogenous L1 mRNAs were evenly distributed
among cytoplasmic and nuclear compartments (Figure 2I).
Moreover, a significant fraction of uridylated L1 mRNAs was de-
tected in the nuclei, suggesting that nuclear re-import of L1
RNPs is not affected.
In sum, we demonstrate abundant uridylation of L1 mRNAs.
Moreover, the data raise a possibility that MOV10 may function-
ally co-operate with TUT4 and TUT7 in uridylating L1 mRNAs.
Inclusion of 30 Uridines Restricts L1 Retrotransposition
To test whether 30 uridylation of L1 mRNAs affects retrotranspo-
sition, we generated a set of L1 megfpI-tagged reporters con-
taining a tRNA-like element that is cleaved off at its 50 end by
endogenous nuclear RNase P, thus yielding L1 reporters with
precisely defined 30 ends. We prepared L1 reporters ending in
homonucleotide tracts of 19A, 26A, 40A, 7U, and 26U, and re-
porters containing 19A, 26A, or 40A plus a variable number of
30 uridines including: 19A1U, 19A3U, 26A1U, 26A2U, 26A3U,1540 Cell 175, 1537–1548, September 6, 201826A4U, 26A5U, 26A6U, 26A14U, 26A26U, 40A1U, and 40A2U,
as well as a reporter lacking any homonucleotide tract – NT (Fig-
ure 3A). Using 30 RACE-seq we confirmed that the reporters
acquire the pre-designed 30 ends in vivo (Figures S3A and
S3B). Remarkably, inclusion of even a single uridine after a
poly(A) tail significantly reduced retrotransposition by up to
35% (Figure 3B). The reduction level increased gradually with
each uridine included at the 30 end of the reporters. The presence
of 5–6 uridines reduced retrotransposition to 25% observed
with the non-uridylated 26A reporter. Oligouridylated reporters
lacking any poly(A) – 7U and 26U, essentially did not support
retrotransposition.
A possible explanation for these results could be a reduction
in the amounts of uridylated reporter L1 mRNAs. We addressed
this question by measuring steady-state levels of a few
selected reporters by RT-qPCR. The oligouridylated L1 re-
porters were observed at lower steady-state levels than their
non-uridylated counterparts (Figure 3B). Nevertheless, the ef-
fects were insufficient to explain the observed reduction in ret-
rotransposition. Importantly, we detected substantial amounts
of the 26A26U, 7U, and 26U L1 reporter mRNAs (at 1/3 of
the 26A reporter levels) despite their inability to support retro-
transposition. This suggests that the effect of uridines on RNA
levels was an important, but not the only, factor in restricting
retrotransposition.
We then tested whether L1-ORF2p can reverse transcribe
substrates ending with uridine residues. We used a modified
version of the L1 element amplification protocol (LEAP) (Kulpa
and Moran, 2006) with the 26A and 26U L1 reporters and 30
adapters comprising 12Ts or 12As and a universal primer
sequence to specifically prime RT of either adenylated or uridy-
lated RNAs by L1-ORF2p. Finally, the cDNAs were amplified by
PCR with reporter and 30 adaptor-specific primers (Figure 3C).
The expected amplification product of 100 bp was only
observedwith complementary adaptor-reporter pairs (Figure 3D,
compare lanes 2 and 5 with lanes 3 and 4). To further ascertain
genuine RT of the 26U reporters, we cloned and sequenced
the 12A-primed LEAP products (lane 5 in Figure 3D). Notably,
20/24 clones had U-tails of a median length of 21.5U, including
clones containing 26Us (Figures S3C and S3D).
We conclude that 30 uridines abolish L1 retrotransposition,
partially through lowering L1 mRNA availability, and that L1-
ORF2p can specifically reverse transcribe uridylated L1 mRNAs.
Differential Effects of TUT4 and TUT7 on L1 mRNA
Abundance, Stability, and Its Translation
The impact of TUT4, TUT7, and MOV10 on L1s’ oligouridylation
and retrotransposition potential prompted us to test their effects
on L1 mRNA steady-state levels and stability and on translation
of L1 proteins.
Northern blotting of poly(A)-selected RNAs is the gold stan-
dard for detecting and quantifying full-length L1 mRNAs (Fig-
ure S4A). To account for our discovery of a substantial fraction
of oligouridylated and 30 truncated L1 mRNAs, we omitted the
poly(A) selection in our Northern blot analyses and could readily
detect abundant expression of full-length L1 reporter mRNAs
(Figure 4A). Notably, we observed a 50% reduction in the
amounts of L1 reporter mRNAs relative to control (MBP) in
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Figure 3. Uridylation of L1 mRNA Abolishes
Retrotransposition
(A) Scheme of the L1 retrotransposition megfpI re-
porters used in this study. Immediately down-
stream of a reporter’s 30 UTR, there is a defined
sequence encoding a non-uridylated or differen-
tially uridylated poly(A) (19A, 19A1U, 19A3U, 26A,
26A1U, 26A2U, 26A3U, 26A4U, 26A5U, 26A6U,
26A14U, 26A26U, 40A, 40A1U,40A2U), 7U, 26U, or
the sequence is missing (‘‘no-tail’’; NT), all followed
by a sequence encoding a tRNA-like element.
(B) Retrotransposition frequency (black) and
steady-state reporter mRNA levels (blue) with the
reporters described in (A). For retrotransposition
assays medians with interquartile ranges are
shown (4 to 12 biological replicates). Blue boxes
plus whiskers (Tukey’s) represent mRNA abun-
dance (8 biological replicates) for the indicated
reporters. Normalizationswere done using the 26A
reporter. One-way ANOVA and Tukey’s multiple
comparison test were used to calculate statistics.
All uridylated reporters support significantly (p <
0.001) lower levels of retrotransposition than their
non-uridylated counterparts. Steady states: 19A
versus 19A3U – ns, 26A versus 26A2U – ns, 26A
versus 26A4U/6U/26U, 7U, 26U – p < 0.001.
(C)Schemeof theLEAPprocedurewithdescription.
(D) LEAP assays using plasmids carrying LINE-1 reporters ending with a defined sequence (26As or 26Us). The reporter used is indicated at the top, and the RT
primer used in each LEAP reaction is indicated below (RT primer). Lanes 1 and 8, a DNA ladder (100 bp to 1,000 bp with 100-bp increments). The 100- and
500-bp bands are labeled. Negative controls (neg.cntrl) without RNPs were also included.
See also Figure S3.TUT4 WT and MOV10 overexpressing cells, which is in line with
the drop in retrotransposition observed under these conditions
(Figures 4A and 4B). Surprisingly, we observed increased
amounts of L1 mRNAs in TUT7WT overexpressing cells (Figures
4A and 4B), consistent with our idea that L1 mRNA availability is
one, but not the key, determinant for L1 retrotransposition.
Although the reason for increased levels of L1 mRNA in TUT7
overexpressing cells remains unclear, the differential effects of
TUT4 and TUT7 on steady-state levels of L1 reporter mRNAs
could possibly be explained by differential localization of those
enzymes in the cell. In fact, we observed that in HEK293 cells
TUT7 was a pan-cytoplasmic protein, but TUT4 and MOV10
were cytoplasmic and clearly co-enriched in cytoplasmic foci
(Figures 4C and 4D). To note, L1-ORF1p co-localized with both
TUT4 and MOV10 in the cytoplasmic foci (Figure S4B; Table
S3), some of which could be P-bodies or stress granules (SG)
as previously described (Doucet et al., 2010).
We next determined the stability of L1 reporter mRNAs using
actinomycin D treatment and multiplex Taq-Man RT-qPCR. In
general, reporter L1 mRNAs are very stable species, exhibiting
an overall stability comparable toGAPDH, and unlikeMYCwhich
decayed rapidly (Figure 4E). Consistent with the Northern blot
data, we observed destabilization of L1 mRNAs when compared
to GAPDH, in TUT4 WT-overexpressing cells, while TUT7 WT
overexpression did not significantly destabilize L1 mRNAs. Sur-
prisingly, in MOV10 overexpressing cells L1mRNAs were as sta-
ble as GAPDH, suggesting that a fraction of L1 mRNAs is gener-
ally stable and insensitive to MOV10-induced RNA degradation
(Figure 4E).To complement these studies, we testedwhether endogenous
L1 mRNAs are influenced by TUT4, TUT7 and MOV10. We
analyzed L1s from HEK293 cells overexpressing WT TUT4,
TUT7, or MOV10 or depleted of these proteins and from PA-1
cells depleted for both TUT4 and TUT7 and TUTases plus
MOV10 (Figures S4C–S4E) using RNA sequencing (RNA-seq).
In line with the northern blot results, overexpression of TUT7,
but not of MOV10 or TUT4, significantly increased expression
of most of L1 subfamilies (Figure 4F; Table S4). Consistently,
we did not observe statistically significant differences in L1
mRNA abundance in HEK293 and PA-1 cells following depletion
of TUT4 and TUT7, MOV10, or both TUTases and MOV10 (Fig-
ures 4G and S4F; Table S5). In addition, we also conducted
RT-qPCR to analyze changes in L1Hs-Ta mRNAs, but we did
not observe statistically significant changes (Figures S4G–S4I).
When combined, these results suggest that regulation of L1 ret-
rotransposition is mostly achieved by qualitative, rather than
quantitative, changes on its mRNAs.
Finally, we tested whether TUT4, TUT7, and MOV10 influence
translation of the L1-encoded proteins. To do that, we con-
structed several plasmids encoding active L1s in which L1-
ORF1p, L1-ORF2p, or both were fused to a fluorescent protein,
or which encoded L1-ORF1p tagged with FLAG (Figures S4J,
S4K, S4N, and S4O). We only detected a slight, but statistically
significant reduction in L1-ORF1p expression (and less so in
L1-ORF2p) in cells overexpressingMOV10and, to a lesser extent,
WT TUT7 and TUT4 (Figures 4H, 4I, S4L, S4M, S4P, and S4R).
Summarizing, L1 mRNAs are stable mRNAs. Their steady-
state levels, stabilities, and translation are only moderatelyCell 175, 1537–1548, September 6, 2018 1541
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Figure 4. Differential Effects of TUT4 and
TUT7 on L1 mRNA Abundance, Stability,
and Translatability
(A) Northern blot of full-length reporter L1 mRNAs,
expressed from a plasmid encoding a full-length
L1.3 lacking a reporter cassette (JM101/L1.3 no
marker) under overexpression of MBP or N’MBP-
tagged TUT4, TUT7, and MOV10 as indicated.
GAPDH served as a loading control. Marks on the
right indicate positions of the RNA reference lad-
der (in thousands of nucleotides) and the position
of 28S and 18S rRNAs is indicated.
(B) Quantification of four northern blots like in (A)
(four biological replicates, three independent ex-
periments) normalized relative to the GAPDH sig-
nals and the MBP sample. One-way ANOVA and
Tukey’s multiple comparison test were used
to calculate statistical significance (*p < 0.05;
***p < 0.001).
(C) Confocal microscopy pictures (maximal pro-
jections in z) depicting HEK293 cells transfected
with plasmids encoding EGFP-TUT4 (top-left
panel) and mCherry-MOV10 (top right, merge on
bottom-left panel) or EGFP-TUT7 (bottom right) to
assess the subcellular localization of proteins.
DNA was stained with Hoechst (cyan). Scale bars
represent 10 or 20 mm as indicated.
(D) Quantitation of MOV10 containing foci in
HEK293 cells that also contain TUT4 or TUT7
(based on co-transfection experiments and
confocal microscopy like in C). For each condition
(TUT4 vs. TUT7), 30 cells were analyzed. Statisti-
cal significance was calculated using a Wilcoxon
signed-rank test (p < 0.0001).
(E) Decay of L1 reporter and endogenous MYC
mRNAs normalized to GAPDH mRNA. Actino-
mycin D was added to cell aliquots for 1–6 hr to
block transcription, followed by RNA retrieval and
estimation of RNA levels by RT-qPCR using multiplexing and Taq-Man probes. Results of three (MYC) or four (L1) independent biological replicates (time-course
assays) are shown (mean values).
(F and G) RNA-seq-based estimation of endogenous L1s expressed in HEK293 cells overexpressing TUT4, TUT7 (stable cell lines), or MOV10 (transient
transfection) (F) or siRNA-depleted of these proteins (G). Uniquely mapped reads for 76 Homo sapiens-specific L1s (after Repbase) were calculated and
normalized to respective controls as indicated. Statistical significances were calculated by DESeq2 for each respective condition pair using summarized counts
of each L1 subfamily and are shown above each pair in (F). No significant changes could be observed in (G).
(H) Analytical flow cytometry of cell populations co-transfected with a pJM101/L1.3-O1EGFP-O2mCherry plasmid and plasmids overexpressing the indicated
proteins. The pJM101/L1.3-O1EGFP-O2mCherry contains a full-length L1.3 element fromwhich the fluorescent EGFP andmCherry cDNAswere cloned in-frame
in the C terminus of L1-ORF1p and L1-ORF2p, respectively. Normalized EGFP and mCherry intensities for data from 8 biological replicates (3 independent
experiments) are shown. Statistical significance was calculated like in (B).
(I) Western blot analysis of FLAG-tagged L1-ORF1p, translated from a full-length L1 without a reporter cassette (pZW-L1RP-O1F; Figure S4N). Co-transfected
plasmids are indicated at the top of the panel. Membranes were probed with anti-FLAG, anti-GAPDH and anti-MBP antibodies to detect respectively: over-
expressed L1-ORF1p-FLAG, GAPDH (loading control), and MBP-tagged proteins. Note that MBP migrates faster than any tagged protein, and it is beyond the
blot and thus not detected.
Data in (B), (D), and (H) are medians with individual points and interquartile ranges shown. See also Figure S4 and Tables S3, S4, and S5.influenced by TUT4, TUT7, and MOV10. We speculate that
the different effects of TUT4 and TUT7 on L1 mRNA levels
and stability may be explained by differential subcellular local-
ization of the TUTases, since only TUT4 is enriched in cyto-
plasmic foci.
TUTases Associate with MOV10
The apparent effect of MOV10 on L1 uridylation (Figure 2D)
prompted us to investigate whetherMOV10might be functioning
in the same pathway as TUTases. To this end, we first tested1542 Cell 175, 1537–1548, September 6, 2018interaction partners of TUT4 and TUT7 by establishing HEK293
FLP-IN T-Rex cell lines stably expressing either TUT4 or TUT7
with an EGFP tag at their N termini (Figures S5A–S5G).
To stabilize evasive interactions, we performed in vivo cross-
linking of proteins with a bifunctional primary amine-reacting
cross-linker: dithiobis(succinimidyl propionate) (DSP). Co-immu-
noprecipitation experiments (coIP) were carried out for cell
lines expressing EGFP-TUT4, EGFP-TUT7, or EGFP (control)
revealing MOV10 as the most specifically enriched protein with
both TUT4 and TUT7 (Figures 5A and 5B; Table S6). In
A B C
D E F
Figure 5. RNA-Dependent Association of TUT4 and TUT7 with MOV10
(A) Mass spectrometry of coIPs with EGFP-TUT4 (6) and controls (6). Normalized mean intensity (semiquantitative measure of protein abundance) and specificity
(quotient of mean intensity in EGFP-TUT4 coIP and in control coIP) are plotted. Only hits identified in at least 3 of 6 EGFP-TUT4 coIPs are shown.
(B) Mass spectrometry of coIPs with EGFP-TUT7 (7) depicted like in (A). Only hits identified in at least 4 of 7 EGFP-TUT7 coIPs are shown.
(C) Mass spectrometry of coIPs with EGFP-MOV10 (7) depicted like in (A). Only hits identified in at least 3 of 7 EGFP-MOV10 coIPs are shown.
(D) Flowchart of experiments used to study RNA-dependence and stability of the TUT4 and TUT7 interactionswithMOV10 (left panel) and results of the respective
experiment (right panel). CoIP was done with EGFP-MOV10 as bait. Lanes 1–4: input and coIP with lysates from control EGFP-expressing cells; lanes 5–13: coIP
with lysates from EGFP-MOV10-expressing cells; lanes 5–8: input proteins; lanes 9–13: enriched proteins without (lanes 9 and 11–13) or with RNase A (lane 10),
washed with increasing salt concentrations as indicated (lanes 11–13). Supernatants after incubation with (lane 14) or without (lane 15) RNase A. Blots were
probed for MOV10, TUT4, TUT7, PABPC1, and GAPDH as indicated. Probing for GAPDH and control coIP was done to show the absence of non-specific
interactions.
(E) TUT7 coIPwith RNA after in vivoUV-crosslinking usingmonoclonal anti-FLAG antibodies and lysates from cells expressing reporter L1 RNAs and either FLAG-
TUT7 or control MBP-TUT7. Enrichment fold was calculated by 2^DDCtmethod, dividing enriched L1 orGAPDHmRNAs in FLAG-TUT7 coIP by their amounts non-
specifically enriched in MBP-TUT7 coIP.
(F) Result of RNA coIP after in vivo UV-crosslinking with FLAG-TUT7 from control cells (transfected with control non-targeting siRNA, CNTRL) or cells depleted of
MOV10 (by siRNA), both transfected with plasmids encoding L1 reporter and FLAG-TUT7. L1 enrichment was calculated by 2^DDCt method of L1 mRNAs en-
riched in each condition and normalized to GAPDH recovered in each condition.
(E and F) Results of four independent biological experiments are shown. Statistical significance was calculated using a two-tailed Mann-Whitney test. Median
values, with individual points and interquartile ranges are shown.
See also Figure S5 and Tables S6 and S7.agreement with the differential subcellular distribution of
TUTases, TUT4 associated stronger with MOV10 than TUT7
(Figures 4C, S5D, and S5E). In a reciprocal coIP with EGFP-
MOV10 we detected TUT4 by LC-MS/MS and TUT7 by a west-
ern blot (Figures 5C and S5H; Table S7). Other specifically
enriched proteins in MOV10 coIP experiments were IGF2BP2
(7 of 7 coIPs), UPF1 and FAM120A, to cite few examples.
Thus, it is clear that MOV10 possesses a wider protein interac-
tome than any of the TUTases.We next validated the interactions
without DSP crosslinking and tested their RNA dependence and
stability (Figure 5D). In the EGFP-MOV10 coIPs TUT4 was en-
riched 10-fold more than TUT7 (Figure 5D, right panel, lanes
9–13). Addition of RNase A significantly reduced the amounts
of enriched TUTases in the coIPs. A similar effect was observed
when increasing concentrations of salt were used to wash the IP
(Figure 5D, lanes 11–13). A poly(A)-interacting PABPC1 also co-
purified with EGFP-MOV10 and showed similar RNA depen-
dence and RNase A sensitivity as TUTases (Figure 5D).To test whether TUT7 interaction with L1 mRNA depends on
MOV10, we performed an RNA coIP experiment employing
UV RNA-protein cross-linking in vivo (Figures S5I–S5K). We
observed superior enrichment (600-fold) of L1 mRNAs in
FLAG-TUT7 coIPs as compared to GAPDH (60-fold) and
normalized to control coIPs with MBP-TUT7 lacking FLAG (Fig-
ure 5E). Importantly, depletion of MOV10 reduced the amount
of enriched L1 mRNA in FLAG-TUT7 coIPs by30% (Figure 5F).
Overall, we show that TUT4, and to a lesser extent TUT7, asso-
ciate with MOV10 in an RNA-dependent and salt-sensitive
manner. Furthermore, we show that TUT7 specifically interacts
with L1 mRNA and that this interaction is partially MOV10
dependent.
MOV10 Facilitates L1 Uridylation by Displacing
L1-ORF1p
To clarify the potential direct role of MOV10 in uridylating L1
mRNAs, we performed biochemical in vitro reconstitutionCell 175, 1537–1548, September 6, 2018 1543
A B C Figure 6. MOV10 Facilitates Uridylation by
Competing with L1-ORF1p
(A) RNA uridylation assay on a 50 32P-labeled
synthetic RNA by recombinant TUT4 in the
absence or presence of recombinant L1-ORF1p
and the indicated helicase/RNPase (HsMOV10,
ScPRP2 or HsSUV3). Lane IN – input RNA; lanes
1–4: uridylation in the absence (1) or presence of
increasing concentrations of rL1-ORF1p (2–4);
lanes 5–8: like in lanes 1–4 but in the presence of
HsMOV10; lanes 9–12: like in lanes 1–4 but in the
presence of ScPRP2; and lanes 13–16: like in lanes 1–4 but in the presence of HsSUV3. The ladder on the right of the panel indicates appended Us.
(B) RNA uridylation levels in the absence or the presence of the indicated helicase proteins were plotted as functions of rL1-ORF1p concentration. Medians of four
independent replicates like in (A).
(C) Results of 5 independent RNA uridylation experiments like in (A) in the absence or presence ofMOV10. Statistical significanceswere calculated using two-way
ANOVA and Bonferroni multiple comparison test. Mean values with SD are shown.
See also Figure S6.experiments. L1-ORF1p has nucleic acid chaperone activity
toward its encoding mRNA (Callahan et al., 2012). We therefore
hypothesized that L1-ORF1p could prevent uridylation of the 30
end of L1mRNA and thatMOV10, known as a functional helicase
(Gregersen et al., 2014) could counteract this effect. To test this
hypothesis, we combined synthetic 32P-labeled RNA without or
with MOV10 and without or with recombinant L1-ORF1p in
increasing concentrations in a buffer containing ATP and UTP.
Uridylation was initiated by the addition of TUT4 WT. L1-ORF1p
indeed inhibited uridylation of RNA in a dose-dependent manner
(Figures 6A, lanes 1–4, 6B, 6C, S6A, and S6B). In the presence of
MOV10andwithout L1-ORF1p, uridylationwasalso inhibited and
the median lengths of oligouridine tails were shorter like in the
control without MOV10 (Figure 6A, lanes 5–8, 6B, and 6C).
Notably, with increasing L1-ORF1p concentrations, MOV10
counteracted the L1-ORF1p adverse effect on RNA uridylation
(Figures 6A–6C). On the other hand, the two other helicase/
RNPase proteins tested: human SUV3 (Pietras et al., 2018) and
yeast PRP2 (Warkocki et al., 2009) did not showsuch effects (Fig-
ures 6A and 6B). To further strengthen our observations, we per-
formed RNase I footprinting experiments. We reasoned that L1-
ORF1p would protect RNA from degradation by RNase I, unless
its bindingwas hindered byMOV10 or it was actively removed by
MOV10. L1-ORF1p indeed tightly protected the entireRNAmole-
cule (Figure S6C, lanes 4 and 5). Remarkably, when MOV10, in
the presence of ATP, was allowed to bind RNA, it prevented pro-
tection of the RNA by L1-ORF1p (Figure S6C, compare lanes 4
and 5 to lanes 7 and 8). Furthermore, if ATP was omitted or if a
catalytically inactive MOV10 mutant was used (K530A) (Gre-
gersen et al., 2014), we observed RNA protection (Figures S6D
and S6E), indicating that the helicase/ATPase activity of
MOV10 is essential for removing L1-ORF1p form L1 RNA.
In sum, we demonstrated the ability of MOV10 to counteract
the chaperone effects of L1-ORF1p on L1 mRNAs, and thus
likely to set the stage for TUT4/TUT7-mediated uridylation.
DISCUSSION
We discovered a mechanism of L1 restriction acting at the level
of L1 mRNA, that relies on MOV10 helicase/RNPase activity fol-
lowed by the uridylation of 30 ends of L1 mRNAs by TUTases.1544 Cell 175, 1537–1548, September 6, 2018Poly(A) tracts were recently shown to be essential for L1 retro-
transposition (Doucet et al., 2015). Nevertheless, the actual
global quality of L1 mRNA 30 ends in human cells had not been
investigated, in part due to technical challenges. We demon-
strated pervasive 30 end uridylation of L1 mRNAs in human cells
and mouse testes, comprising molecular niches where L1 are
transcribed and thus post-transcriptional regulatory mecha-
nisms are expected to operate. We propose that this abundant
uridylation of L1 mRNAs provides a general, specific, and effi-
cient way of restricting retrotransposition of active L1s.
This study allowed us to propose a model of MOV10-TUT4/
TUT7-driven restriction of retrotransposition in mammalian cells
(Figure 7). Following transcription in the nucleus, L1 mRNA is ex-
ported to the cytoplasm where translation of the L1-encoded
proteins occurs. L1mRNAs faceMOV10, which had been shown
in several independent studies to be a potent restriction factor of
retrotransposition (Arjan-Odedra et al., 2012; Choi et al., 2018;
Goodier et al., 2012; Li et al., 2013; Lu et al., 2012; Skariah
et al., 2017). Despite efficient production of L1-ORF1p, newly
synthesized L1-ORF1p is likely in constant kinetic competition
with MOV10 (Naufer et al., 2016). Direct binding of L1 mRNAs
by MOV10 was previously demonstrated by cross-linking and
immunoprecipitation (Gregersen et al., 2014), with the highest
MOV10 occupancy just 50 and within the L1 30 UTR. Given its
50/30 directionality (Gregersen et al., 2014), MOV10 likely
moves along the L1 30 UTR toward the 30 end of this RNA to prime
its uridylation by TUT4/TUT7 (Figures 6 and S6). Although canon-
ical uridylation of mRNA has been suggested to reduce their
mRNA life time (Lim et al., 2014), in the case of L1 this effect
seemed to depend on the subcellular localization of the uridy-
lated L1 mRNA. Remarkably, canonically polyadenylated L1 re-
porter and endogenous L1 mRNAs were slightly stabilized by
TUT7 WT, but not TUT4 WT (Figure 4), which likely might be ex-
plained by the differential localization of those enzymes in the
cytoplasm with TUT4 enriched in cytoplasmic foci (Figure 4).
Thus, here we showed that uridylation by TUT4 and TUT7 differ-
entially affects the fate of the uridylated RNA. Nevertheless, L1
reporters with pre-defined uridylated 30 ends were indeed less
stable than their adenylated counterparts (Figure 3).
Uridylated endogenous L1 mRNAs could access the nucleus
(Figure 2) where de novo L1 insertions are accumulated via
Figure 7. Model of Restriction of L1 Retro-
transposition by UridylationTPRT (Jurka, 1997). During TPRT, the endonuclease activity of
L1-ORF2p nicks dsDNA at a consensus sequence (50TTTT/AA
and variants), exposing a dT stretch that might promote base-
pairing with the L1 poly(A) tail (Cost et al., 2002; Feng et al.,
1996; Jurka 1997). The recently proposed ‘‘snap-velcro’’ model
for initiation of RT by human L1-ORF2p (Monot et al., 2013) sug-
gests that RT initiation is dependent on the degree of comple-
mentarity between the 30 end of the L1 mRNA and the exposed
genomic DNA present at the site of L1-ORF2p endonuclease
nicking. The most important residues for this process are the
four 30-most nucleotides (the ‘‘snap’’). Thus, 30 uridylated L1
mRNAs could not base-pair efficiently with the short exposed
dT genomic sequence, and as a consequence any uridine pre-
sent at the 30 end of L1 mRNAs will greatly diminish its compe-
tency for RT initiation (Figure 3). While it is feasible that RT is
initiated by L1-ORF2p within the poly(A) tract, irrespective of ter-
minal 30 uridines, the very weak retrotransposition potential of
the 26A6U, 26A14U, and 26A26U L1 reporters (Figure 3) sug-
gests that such internal priming must be highly inefficient.
In sum, our data suggest that uridylation is amajor mechanism
of retrotransposition control in mammals, as it can act in all cell
types where L1s retrotranspose. Although this hypothesis re-
quires further testing, recent discoveries that female mice with
a conditional double-knockout of TUT4/TUT7 are infertile (Mor-
gan et al., 2017) are an interesting coincidence because high
levels of L1 transcription occur in the germline.STAR+METHODS
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TaqMan primers and probe with FAM dye
(TAQMAN_EGFPI_2_PROBE)
Thermo Fisher Scientific 4331348
Actinomycin D Roth 8969.1
Deposited Data
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The scripts used to analyze the RACE-seq data This paper https://github.com/smaegol/
LINE_1_RACE_seq_analysis
Data used for Figure production and maps
of the created plasmids
This paper http://dx.doi.org/10.17632/zkb2nr99rw.1
Experimental Models: Cell Lines
HEK293 FLP–In T–Rex EGFP–TUT4 ADZ Lab; This paper N/A
HEK293 FLP–In T–Rex EGFP–TUT7 ADZ Lab; This paper N/A
HEK293 FLP–In T–Rex EGFP–MOV10 ADZ Lab; This paper N/A
HEK293 FLP–In T–Rex parental Invitrogen R78007
HEK293T Invitrogen N/A
Human foreskin fibroblasts (HFFs). Jose L. Garcia-Perez Lab;
cells originally purchased
from ATCC; This paper
N/A
Human embryonic carcinoma PA-1 Jose L. Garcia-Perez Lab;
cells originally purchased
from ATCC; This paper
N/A
Human embryonic stem cells H9 Jose L. Garcia-Perez Lab;
cells originally purchased
from Wicell; This paper
N/A
Neuron progenitor cells (NPCs differentiated
from H9-hESCs)
Jose L. Garcia-Perez; We
differentiated hESCs to NPCs
using a previously validated
protocol (Macia et al., 2017);
This paper
N/A
FreeStyle 293-F cells Invitrogen R79007
Experimental Models: Organisms/Strains
C57BL/6/Tar mice Animal facility University
of Warsaw
N/A
Oligonucleotides
RA3_15N (30 adaptor) /5rApp/CTGACNNNNNNNN
NNNNNNNTGGAATTCTCGGGTGCCAAGG/3ddC/
Integrated DNA Technologies;
This paper
67719860
Spike-in_0 (without poly(A); fixed index = 19) AAT
GATACGGCGACCACCGAGATCTACACGTTCA
GAGTTCTACAGTCCGACGATCNNNNNNNNNN
NNNNNNNNNNNNNCTGACGAGCTACTGTTG
GAATTCTCGGGTGCCAAGGAACTCCAGTCAC
GTGAAAATCTCGTATGCCGTCTTCTGCTTG
Integrated DNA Technologies;
This paper
70242976
Spike-in_8 (fixed index = 20) AATGATACG
GCGACCACCGAGATCTACACGTTCA
GAGTTCTACAGTCCGACGATCNNNNNN
NNNNNNNNBAAAAAAAACTGACGAGC
TACTGTTGGAATTCTCGGGTGCCAAGGAA
CTCCAGTCACGTGGCCATCTCGTATGC
CGTCTTCTGCTTG
Integrated DNA Technologies;
This paper
70242977
Spike-in_16 (fixed index = 21) AATGATA
CGGCGACCACCGAGATCTACACGTTCA
GAGTTCTACAGTCCGACGATCNNNNN
NNNNNNNNNBAAAAAAAAAAAAAAAA
CTGACGAGCTACTGTTGGAATTCTCGG
GTGCCAAGGAACTCCAGTCACGTTTCGATC
TCGTATGCCGTCTTCTGCTTG
Integrated DNA Technologies;
This paper
70242978
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Spike-in_32 (fixed index = 22) AATGATACGGCGA
CCACCGAGATCTACACGTTCAGAGTTCTACAGTC
CGACGATCNNNNNNNNNNNNNNBAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAACTGACGAGCTACTG
TTGGAATTCTCGGGTGCCAAGGAACTCCAGTCAC
CGTACGATCTCGTATGCCGTCTTCTGCTTG
Integrated DNA Technologies;
This paper
70242979
Spike-in_64-5 (for splint ligation with the 30 part)
AATGATACGGCGACCACCGAGATCTACACGTTC
AGAGTTCTACAGTCCGACGATCNNNNNNNNNN
NNNNBAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAC
Integrated DNA Technologies;
This paper
70242980
Spike-in_64-3-P (for splint ligation with the 50 part;
fixed index = 23) /5Phos/TGACGAGCTACTGTTGGA
ATTCTCGGGTGCCAAGGAACTCCAGTCAC
GAGTGGATCTCGTATGCCGTCTTCTGCTTG
Integrated DNA Technologies;
This paper
70242981
Spike-in splint (for splint ligation) TCCAACAG
TAGCTCGTCAGTTTTTTTTTTTTTTTTT
Integrated DNA Technologies;
This paper
N/A
RNA44 CGACUGGAGCACGAGGACACUGACAUG
GACUGAAGGAGUAGAAA
Future Synthesis;
This paper
N/A
Stealth RNAi siRNA Negative Control Hi GC Invitrogen 12935400
siRNA; for detailed information on all other siRNAs
used see Table S1
Invitrogen 10620318/ 10620319
For detailed information on all other oligonucleotides
used see Table S1
N/A N/A
Recombinant DNA
99 PUR RPS EGFP; a wild-type LINE-1 RP
retrotransposition megfpI reporter
John Goodier;
Goodier et al., 2012
N/A
99 PUR JM111 EGFP; a retrotransposition
incompetent (due to L1-ORF1p mutations) LINE-1
RP retrotransposition megfpI reporter
John Goodier;
Goodier et al., 2012
N/A
JM101/L1.3 nomarker; a LINE-1 L1.3 element under
CMV promoter without a reporter sequence
Jose L. Garcia Perez Lab;
Wei et al., 2001; This paper
N/A
JM101/L1.3–O1EGFP–O2cherry (EGFP–tagged
L1–ORF1p, mCherry–tagged L1–ORF2p, on a
full–length L1.3 element containing the mneoI
retrotransposition indicator cassette)
Jose L. Garcia Perez Lab;
This paper
N/A
pZW-L1RP-O1F (FLAG-tagged L1-ORF1p on a
full-length L1RP element)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP–O1F–megfpI (FLAG-tagged L1–ORF1p
on a full-length L1RP element tagged with the
megfpI retrotransposition indicator cassette)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP-O1mCh (mCherry-tagged L1-ORF1p
on a full-length L1RP element)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP-O1mCh-megfpI (mCherry-tagged
L1-ORF1p on a full-length L1RP element tagged
with the megfpI retrotransposition indicator cassette)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP–O2G (EGFP-tagged L1–ORF2p on a
full-length L1RP element)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP–megfpI (Active full-length L1RP element
tagged with the megfpI, containing a CMV promoter
upstream of L1RP, giving high retrotransposition
rates without a need for antibiotic selection)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
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pZW–L1RP–megfpI–TRL (‘‘blunt ended’’ L1RP megfpI
reporter due to excision of the tRNA-like element,
see below for details)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW–L1RP–megfpI–xyz–TRL (megfpI tagged L1RP
where xyz specifies the 30 tail, for example 26A
or 19A3U see methods for details)
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
pZW plasmids for generation of stable cell lines and
transient overexpression of TUT4, TUT7, MOV10,
TENT4B, TENT2 proteins with N-terminal EGFP,
mCherry, MBP or FLAG tags
ADZ Lab; This paper Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
Plasmid for overexpression of TUT1-FLAG ADZ Lab; Mroczek and
Dziembowski, 2013
Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
Plasmid for overexpression of TENT5C-FLAG ADZ Lab; Mroczek et al., 2017 Mendeley data https://doi.org/
10.17632/zkb2nr99rw.1
Software and Algorithms
Prism 5 for Windows GraphPad Software https://www.graphpad.com/
scientific-software/prism/
Attune NxT flow cytometry software provided
with the Attune NxT instrument
Thermo Fisher Scientific N/A
MultiGauge 5.1 Fuji Film (discontinued) N/A
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
SnapGene 3.3.4 GSL Biotech LLC http://www.snapgene.com/
MaxQuant 1.3.0.5. Max Planck Institute
for Biochemistry;
Cox and Mann 2008
http://www.coxdocs.org/doku.php?
id=maxquant:common:download_
and_installation#download_and_
installation_guide
Flowing Software Perttu Terho http://flowingsoftware.btk.fi/
Tailseeker3 Chang et al., 2014 https://github.com/hyeshik/tailseeker
TEToolkit Jin et al., 2015 https://github.com/mhammell-
laboratory/tetoolkit
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
Repeatmasker Smit, AFA, Hubley,
R & Green
http://www.repeatmasker.org/
Sabre N/A https://github.com/najoshi/sabre
RACE-seq analysis scripts This paper https://github.com/smaegol/
LINE_1_RACE_seq_analysisCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to the Lead Contact, Andrzej Dziembowski (andrzejd@ibb.waw.pl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
We use standard procedures to derivate and cultivate all cell types used in this study (see below for a detailed description of these
methods). Absence ofMycoplasma spp. was confirmed at least once amonth and STR-genotypingwas used to control the identity of
the cell lines (Lorgen, Spain).
HEK293 FLP-IN T-Rex and HEK293T cells
HEK293 cells were derived from a female. HEK293 FLP-In T-Rex cells were purchased from Invitrogen. The cells were cultured in
monolayers in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO) supplemented with 10% fetal bovine serum (FBS w/o tetracy-
cline, GIBCO) at 37C in a 5% CO2 incubator.e4 Cell 175, 1537–1548.e1–e17, September 6, 2018
HeLa-HA and PA-1 cells
HeLa-HA (Hulme et al., 2007) and human embryonic carcinoma PA-1 (Thomson et al., 1998) were derived from females.
The cells were cultured in monolayers in minimal essential medium (MEM, GIBCO) supplemented with L-glutamine and 10% heat-
inactivated fetal bovine serum (FBS, GIBCO) at 37C in a 5% CO2 incubator.
Human foreskin fibroblasts
Human foreskin fibroblasts (HFFs, passage 3-10, from ATCC) were only used to generate Conditioned Media (CM). HFFs were
grown following the provider’s instructions in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 25 mM HEPES,
2 mM L-glutamine and 10% heat-inactivated FBS.
H9-human embryonic stem cells
WA09/H9 human embryonic stem cells (hESCs) are female cells. The cell line was obtained from Wicell and was maintained in HFF-
conditioned media (HFF-CM) using Matrigel-coated plates as described (Garcia-Perez et al., 2007; Macia et al., 2017). To prepare
HFF-CM, HFFs were inactivated by g-irradiation with 3000-3200 rads, seeded in T225 flasks (3x106 cells/flask) and cultured in hESC
media for 24h (DMEMKnockOut supplemented with 4 ng/ml b-FGF, 20%Knockout serum replacement, 1 mM L-Glutamine, 0.1 mM
b-mercaptoethanol and 0.1mMnon-essential amino acids). HFF-CMwas collected and frozen until used, andwe harvestedHFF-CM
during seven consecutive days. HESCs were passaged manually using a cell-scraper as described (Garcia-Perez et al., 2007; Macia
et al., 2017).
HESC-NPCs were cultured in KnockOut DMEM/F-12 with Stem Pro Neural Supplement, 1 mM L-Glutamine and Penicillin-Strep-
tomycin (10,000 U/mL). All the cell lines were grown in a humidified 7% CO2 incubator at 37
C.
HESC-derived Neuronal Progenitor Cells
To differentiate hESCs to neuronal progenitor cells (NPCs), H9-hESCs were initially cultured for 2 days in N2media (DMEM/F12 + N2
supplement (Invitrogen)) containing 10 mm SB-431542 (Sigma) and 1 mm dorsomorphin (Calbiochem). After 2 days, hESCs were
collected from plates using a cell-scraper. To generate embryoid bodies (EBs), hESCs were seeded in low-attachment plates using
N2 media containing 10 mm SB-431542 (Sigma) and 1 mm dorsomorphin (Calbiochem). EBs were cultured for 4-6 days, with daily
changes of media. Next, EBs were plated in Matrigel-coated plates (60-mm plates) and cultured during 5-7 days on NB medium
(0.5x N2, Invitrogen; 0.5x B-27, Invitrogen; 20 ng/ml FGF-2, Miltenyi Biotec and 1% penicillin-streptomycin), replacing media every
other day. After 5-7 days, neuronal rosettes were manually collected, dissociated and plated on poly-L-ornithine (Sigma)/laminin
(Invitrogen) coated plates using NB medium. Upon reaching confluence, NPCs were detached from plates using StemPro Accutase
Cell Dissociation Reagent (Invitrogen), passaging in a 1:3 ratio. NPCs were grown for < 10 passages.
Mouse testes
Testes were isolated from 4 P10 young wild-type C57BL/6/Tar mice. The mice were maintained according to national regulations
http://www.dziennikustaw.gov.pl/du/2015/266/D2015000026601.pdf. Prior to the experiment, the animals were kept in the labora-
tory animal facility with free access to food and water with a 12 h light/dark cycle.
METHOD DETAILS
Cloning
Plasmids for TUT4/7, MOV10 and other TENTs overexpression
The pcDNA5 FRT/TO-derived plasmids used in this studywere generally named using pZWas a prefixwith respective tag and protein
names specified. Generation of pZW-EGFP-ZCCHC6, pZW-EGFP-ZCCHC11, pZW-EGFP-ZCCHC6_D1060A, pZW-EGFP-
ZCCHC11_D1011A plasmids for establishing stable cell lines expressing N-terminally EGFP-tagged TUT4 (ZCCHC11) or TUT7
(ZCCHC6) or their catalytically inactive mutant versions was described in qabno et al. (2016b). For the sake of this study following
plasmids were prepared: pZW-EGFP-MOV10, pZW-EGFP-MOV10_K530A, pZW-EGFP-MOV10_D645N, pZW-FLAG-TUT7, pZW-
FLAG-TUT7_D1060A, pZW-MBP-TUT4, pZW-MBP-TUT4_D1011A, pZW-MBP-TUT7, pZW-MBP-TUT7_D1060A, pZW-mCherry-
MOV10, pZW-mCherry-TUT4, pZW-mCherry-TUT4_D1011A, pZW-mCherry-TUT7, pZW-mCherry-TUT7_D1060A. Other plasmids
used in the study were plasmids for overexpression of C-terminally FLAG-tagged TUT1, TENT4B, TENT2, TENT5C. All plasmids
were generated using Sequence and Ligation-Independent Cloning procedures (SLIC) (Li and Elledge, 2012) andmethods described
in details in Szczesny et al., 2018. Briefly, the respective cDNA inserts were generated by standard PCR using custom DNA oligo-
nucleotides (as specified in the Table S1) comprising a common pcDNA5 FRT/TO sequence for homologous recombination in bac-
teria including either AgeI or NheI restrictase restriction sites and a cDNA specific sequence. Phusion HF polymerase and cycling
conditions depending on the insert size to be amplified (assuming30sec for 1kb) were used. For generating site-specific mutations
in TUT4, TUT7 andMOV10 genes splint PCRwas used i.e., first two fragments were amplified with outer primers and internal primers
comprising the desired nucleotide change. Thereafter, gel-purified fragments were mixed in 1-to-1 molar ratio and used as a tem-
plate for PCR with outer primers only to generate full-length insert with a desired nucleotide change (see Table S1). The amplified
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DNA bands were excised and DNA purified using ‘gel out’ kit (A&A Biotechnology). 50ng – 150ng purified insert were mixed with
100ng AgeI and NheI digested pcDNA5 FRT/TO derivative (Szczesny et al., 2018) in 1X buffer G with 0.1 mg/ml BSA (Thermo Sci-
entific) in the presence of 0.6U T4 DNA polymerase (NEB) in 10 mL and incubated at room temperature for 2 min. Then dATP was
added to 1 mM and reactions incubated at 37C for 2 min, followed by incubation in ice and addtion to a MH1 bacterial chemicom-
petent cells’ aliquot for a standard heat-shock transformation procedure. The cells were spread onto 100 ng/ml amplicilin-containing
agar plates. Single colonies were used to isolate plasmids, followed by restriction analysis and sequencing. All parental plasmids
(w/o inserts) were made available through the Addgene repository (https://www.addgene.org/Andrzej_Dziembowski/).
30 homonucleotide tracts in L1 megfpI reporters
An L1RP element lacking its 5 ‘UTR and containing themegfpI retrotransposition indicator cassette was recloned as an entire frag-
ment fromplasmid 99 PURRPSEGFP (Ostertag et al., 2000) into plasmid pZW-HSVTKpA (comprising the universal Multi Cloning Site
of pKK (see Szczesny et al. [2018]), a puromycin resistance gene (PAC) instead of the original hygromycin gene, and a HSV polya-
denylation site instead of the original bGH polyadenylation site) by PCR amplification using the forward primer ORF1f2 (see Table S1)
and reverse primer LINE-1rep_NheI and Sequence and Ligation Independent Cloning (SLIC) into AgeI and NheI sites to yield the
pZW-L1RP-megfpI-HSVTKpA plasmid. This plasmid was then cleaved with SrfI (New England Biolabs) and NotI FD (Thermo Fisher
Scientific) restriction enzymes, followed by dephosphorylation with FastAP (Thermo Fisher Scientific).
Synthetic long DNA comprising part of the SrfI site, the desired 30 L1 end sequence, a sequence encoding a full tRNA-like element
cleavable at its 50 end by endogenous RNase P (see Doucet et al. [2015]) and part of the NotI site were ordered from IDT: xyz_for
(GGGC(xyz)GACGCTGGTGGCTGGCACTCCTGGTTTCCAGGACGGGGTTCAAGTCCCTGCGGTGTCTGC) xyz_rev (GGCCGCAGA
CACCGCAGGGACTTGAACCCCGTCCTGGAAACCAGGAGTGCCAGCCACCAGCGTC(zyx)GCCC); where (xyz) in the forward
primer specifies either of: 19A, 19A1U, 19A3U, 26A, 26A1U, 26A2U, 26A3U, 26A4U, 26A5U, 26A6U, 26A14U, 26A26U, 40A,
40A1U, 40A2U, 7U, 26U and where (zyx) in the reverse primer specifies a complementary sequence. In case of the ‘‘no tail’’ reporter
there was no additional sequence in the place of (xyz) and (zyx) in the respective forward and reverse primers.
The primers were either ordered with a 50 phosphate or phosphorylated using PNK (NEB) and annealed after pooling the respective
pairs in PNK reaction buffers at a 1:1 ratio (10 pmol each; 20 mL total volume) and addition of water to a volume of 100 mL followed by
heating to 95C for 10 min (simultaneous enzyme deactivation), 75C for 2 min, 55C for 2 min and cooling to RT.
Following this step, the annealed oligonucleotides were combined with the SrfI/NotI- cleaved dephosphorylated plasmid and
ligated for 1h at 22C using T4 DNA ligase (NEB).
The resulting plasmids were named pZW-L1RP-megfpI-xyz-TRL, where xyz indicates the precise end of each L1 mRNA, and are
listed in the Key Resources Table.
Plasmidswere produced from100mLMH1 E. coli cultures using a PlasmidMidi kit (A&ABiotechnology), sequenced and validated.
Tagging L1-ORF1p with FLAG
Two DNA fragments were amplified using the 99 PUR RPS EGFP plasmid as a template. The 50 fragment encompassed the
L1-ORF1p CDS without the 50 UTR and a sequence encoding the FLAG tag attached directly to L1-ORF1 lacking the stop codon,
which was moved to the end of the FLAG tag. The 30 fragment encompassed the FLAG-stop codon-linker-L1-ORF2 CDS with or
without themegfpI reporter cassette. The 50 fragment primers were (see Table S1): forward primer ORF1f2,reverse primer SOPO1Fr1.
The 30 fragment primers: forward primer SOPO1Ff2, reverse primer for L1 w/o reporter SOPO21r2 and reverse primer for L1 with
megfpI reporter SOPO21r3. The 50 and 30 fragments were combined in 1:1 molar ratios and used in a splice PCR with the 50 and
30 outer primers. Finally, the purified splice PCR product was inserted into the HindIII and XhoI sites of pKK-NoTag (Szczesny
et al., 2018) by SLIC. The plasmids pZW-L1-O1F and pZW-L1-O1F-megfpIwere prepared from 100mL bacterial cultures, the inserts
were sequenced and retrotranspositional competence was validated.
Tagging L1-ORF1p with mCherry
Tagging was accomplished as described above for pZW-L1RP-O1F, but themCherry reference sequence and L1-ORF1p CDSwere
first amplified and used in splice PCR to create a joint L1-ORF1-mCherry 50 fragment. This fragment was then combinedwith either of
the 30 fragments (i.e., lacking or carrying themegfpI reporter cassette sequence) and used in splice PCR. The insert was cloned be-
tween the HindIII and XhoI sites of the pZW-HSVTKpA plasmid. Primers used to produce the mCherry fragment were (see Table S1):
ORF1_mCherry_for (forward) and ORF1_mCherry_rev (reverse). Additionally, for L1-ORF1 CDS amplification, the L1-ORF1 reverse
primer ORF1_mChtag_rev was used instead of SOPO1Fr1. For Linker-ORF2 CDS amplification (both without and with megfpI), the
forward primer L1_linker_for was used instead of SOPO1Ff2.
Plasmids pZW-L1RP-O1mCh and pZW-L1-O1mCh-megfpI were prepared from 100 mL bacterial cultures, the inserts were
sequenced and we next demonstrated that these constructs retain their retrotransposition potential in cultured cells.
Tagging L1-ORF2p with EGFP
Tagging was accomplished by recloning LINE-1 RPS from the 99 PUR RPS EGFP plasmid into pKK-TEV-mEGFP linearized with
BstHI (AgeI) and NheI restriction enzymes using described protocols (Szczesny et al., 2018).
Primers used to PCR amplify a single insert encompassing the LINE-1 RPS (without the 50 UTR and themegfpI retrotransposition
indicator cassette) were: L1Orf1f (forward; see Table S1) and L1r-Stp (reverse).The obtained plasmid pZW-L1RP-O2-Gwas prepared
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Tagging both L1 ORFs with EGFP and mCherry
To generate plasmid JM101/L1.3-O1EGFP-O2cherry, we used a cloning strategy very similar to the one described above (available
upon request). The final construct was fully sequenced. The vector includes an mneoI retrotransposition indicator cassette, which
allowed us to demonstrate that tagging both L1-encoded proteins with fluorescent proteins does not significantly affect retrotrans-
position efficiency in cultured cells.
Stable cell lines – generation and validation
Related to Figures 5 and S5. Stable cell lines were generated using human HEK293 FLP-In T-Rex cells (Invitrogen) and the FLP-In
T-Rex system (Invitrogen). The cells were seeded in 6-well plates (Greiner) at 0.5x106 cells per well. On the following day (20h
post seeding), the medium was replaced and cells in a single well were transfected with 0.2 mg pOG44 plasmid and 1.8 mg pZW
plasmid encoding either of the N-terminally EGFP-tagged human TUT4, TUT7, MOV10 or TUT4/7 mutant versions encoding catalyt-
ically inactive proteins using 5 mL Lipofectamine 2000 (ThermoFisher Scientific). At24h post-transfection the cells were trypsinized
and seeded onto 60-mm dishes (Greiner) in medium supplemented with 50 mg/ml hygromycin (Invitrogen). Cells were selected for
12-18 days and the medium was exchanged every 2-3 days. No further clonal selection was performed.
Tetracycline-inducible expression of EGFPwas tested using titration of tetracycline from 25 to 100 ng/ml in 6-well plates. The cells
were harvested and lysed, with the lysates used for western blotting (see below) with anti-EGFP and anti-ZCCHC11, ZCCHC6 or
MOV10 antibodies. The cells were also analyzed by flow cytometry. Prior to analysis, the cells were detached from the plates by tryp-
sinization, followed by addition of media and centrifugation at 350 rcf. for 3 min. The medium was removed and the cells were sus-
pended in 1 mL PBS. EGFP signals were measured using a FACScalibur instrument (BD Biosciences) and the data were analyzed
using Flowing software (http://flowingsoftware.btk.fi/) or Cyflogic software (CyFlo, Ltd.).
Maximal expression of the EGFP-tagged proteins was observed withR 25 ng/ml tetracycline.
Cell compartment fractionation
Related to Figures S4C, S5F, and S5G. Cells (HEK293, HeLa and PA-1) were fractionated into cytoplasmic and nuclear compart-
ments using the REAP fractionation method described by Suzuki et al., 2010.
Related to Figure 2I. To separate cytoplasmic and nuclear RNA, we used 200 mL 1x PBS, 0.1% Igepal CA-630, 5 mM EDTA to
extract cytoplasmic RNA, after which the nuclei were pelleted by 10 s centrifugation at 5000 rcf. and 200 mL of the cytoplasmic frac-
tion (supernanant) taken for RNA isolation. Nuclear pellet was resuspended and washed and pelleted twice with additional 200 mL of
the buffer. The nuclei were then pelleted and resuspended once again in the buffer. The 200 mL fractions were used for RNA extraction
with 1 mL TRI-reagent (Sigma) according to the manufacturer’s recommendations.
Western blotting
Cells from a single well of a 6-well plate were detached with PBS (HEK293) or trypsinized (HeLa, PA-1) and pelleted by centrifugation
at 350 rcf. for 3 min. Cells were lysed by pipetting the entire pellet 10-20 times in 30 mL 0.5x PBS/0.15% NP40 supplemented with
protease inhibitors as well as viscolase, a DNA and RNA nuclease (A&A Biotechnology), added to 0.1 U/ml. The mixtures were incu-
bated at 37C for 15 min with occasional shaking to allow digestion of nucleic acids before 20 mL 3x SDS-PAGE loading buffer with
30 mM DTT was added. The mixture was then boiled and loaded onto 10% SDS-PAGE gels.
After SDS-PAGE, the proteins were transferred to Protran nitrocellulose membranes (GE Healthcare) by wet transfer at 40 V
300 mA for 2h at 4C in 1x transfer buffer (25 mM Tris-HCl, pH 7.5, 192 mM glycine, 0.1% SDS, 20% methanol).
Membranes were stained with 0.3% w/v ponceau S in 3% v/v acetic acid, and the staining pattern was digitized. The ponceau S
stain was removed and membranes were incubated with 4%w/v skim milk in TBST20 buffer followed by incubation with specific pri-
mary antibodies (see Key Resources Table) diluted 1:1,000 (TUTases, FLAG) or 1:2,500 (MOV10, GAPDH, tubulins, EGFP, PABP) at
10C for 14-20 h. Membranes were washed 3 times for 20 min each in TBST20, and then incubated with HRP-coupled secondary
antibodies (anti-rabbit or anti-mouse; Jackson Bioscience) at 1:5000 to 1:30000 (depending on the expected amount of protein)
in 4% skim milk in TBST20. The membranes were washed 4 times for 20 min each with TBST20 and the proteins were detected using
an ECL kit (Bio-Rad). The ECL signals were digitized with a CCD camera (Alpha Innotech) or exposed to films (CL-Exposure, Thermo
Scientific) and developed in AGFA Curix CP-1000 device.
Co-immunoprecipitation
Related to Figure 5 and Tables S5, S6, and S7. HEK293 FLP-In T-Rex cells stably expressing EGFP (control), EGFP-TUT4, EGFP-
TUT7 or EGFP-MOV10 cultured for 7-10 days in the absence of tetracycline. Between 40 and 48h before harvesting, the cells
were plated onto four 145 mm dishes (Greiner) in medium containing 25-100 ng/ml tetracycline. After 40-48h the medium was
removed and the cells were gently washed twice with room-temperature PBS. Thereafter, dithiobis (succinimidyl propionate)
(DSP, Pierce) freshly prepared in DMSO was diluted in room-temperature PBS to 2 mM in 10 mL and overlaid onto the cells. Cells
were incubated with PBS/DSP for 30-45 min at 10C prior to removing the solution and harvesting the cells by scraping (with rapid
buffer flow from a 5 mL pipette tip) into ice-cold 100 mM Tris-HCl (pH 8.0)/PBS (to stop DSP primary-amine reactivity) and centrifu-
gation at 500 rcf. for 5 min in 50 mL tubes (BD). The cell pellets were either processed directly or flash frozen in liquid nitrogen and
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Prior to analysis, the cells were suspended and lysed in 2.5 mL 1x lysis and binding buffer (20 mM HEPES-KOH, pH 7.1, 100 mM
NaCl, 0.5% Igepal CA-630 (NP40), 3 mM MgCl2, 10% glycerol, with 2 mM benzamidine, 0.6 mM leupeptin, 2 mM pepstatin A and
1 mM PMSF as protease inhibitors and 0.1 mg/ml RNase A) for 30 min on ice before sonication. Crude lysates were centrifuged
at 16,000 rcf. at 4C for 15 min in low protein-binding siliconized tubes (Eppendorf or Sigma). Cleared lysates were mixed with
100 mL magnetic beads coupled with GFP-Trap nanobody and incubated at 10C for 1h with head-over-tail rotation. The lysates
with unbound proteins were removed and the beads with bound proteins were washed 6 times with 1x washing buffer (as for 1x lysis
and binding buffer but with 0.5 M NaCl). The proteins retained on the beads were released by boiling with 120 mL release buffer (3%
SDS, 50 mM Tris-HCl pH 8.0, 50 mM DTT, 10% glycerol) for 5 min. Part (1/10) of the material was analyzed by SDS-PAGE and silver
staining and the remainder was precipitated using methanol-chloroform and analyzed by LC-MS/MS (see below).
Related to Table S5. ORF1-FLAG pull-downs were done using HEK293 FLP-IN T-Rex cells with tetracycline-inducible expression
of full-length LINE-1 RPS with L1-ORF1p-FLAG. The co-IP was done as described above.
LC-MS/MS
Proteins were dissolved in 100 mL 100 mM ammonium bicarbonate buffer, reduced in 100 mM DTT for 30 min at 57C, alkylated in
55mM iodoacetamide for 40min at RT in the dark and digested overnight with 10 ng/ml trypsin (V5280, Promega) at 37C. To stop the
digestion, trifluoroacetic acid was added at a final concentration of 0.1%. Themixture was centrifuged at 14,000 rcf. at 4C for 20min
to remove precipitated material. MS analysis was performed by LC-MS in the Laboratory of Mass Spectrometry (IBB 334 PAS, War-
saw) using a nanoAcquity UPLC system (Waters) coupled to a LTQ-Orbitrap Velos or QExactive mass spectrometer (Thermo Fisher
Scientific). Themass spectrometer was operated in the data-dependent MS2mode, and data were acquired in them/z range of 300-
2,000. Peptides were separated by a 180 min linear gradient of 95% solution A (0.1% formic acid in water) to 35% solution B (0.1%
formic acid in acetonitrile). Each sample measurement was preceded by three washing runs to avoid cross-contamination.
UV-crosslink of LINE-1 mRNA to FLAG-TUT7
Related to Figures 5E, 5F, and S5I–S5K. 8x106 293T cells were seeded onto 6 145-mm culture dishes. Next day the cells (each dish)
were transfected with 300 pmoles non-targeting control siRNA (stealth siRNA, Invitrogen) or MOV10-targeting siRNA (C; in the Key
Resources Table) using 60 mL Lipofectamine RNAiMAX (Invitrogen) in 5 mL OPTI-MEM (GIBCO; to 20ml medium). Next day, cells
were trypsinized and 10x106 cells of each condition were placed onto 2 new 145-mm dishes. Next day, to overexpress LINE-1
and TUT7 the cells (each dish) were transfected with 15 mg pZW-L1RP-megfpI and 15 mg either pZW-MBP-TUT7 (control) or
pZW-FLAG-TUT7 using 60 mL Lipofectamine2000 (Invitrogen) in 5 mL OPTI-MEM (GIBCO; to 20ml medium). Cells were allowed
to propagate for 36-40h followed by media removal, careful washing of the cells attached to the dish with 2x 18 mL PBS (room
temperature). Thereafter, cells were overlaid with 5 mL PBS and placed on a tray with ice and water. Cells were irradiated with 4x
120 mJ/cm2 in a UV crosslinker (UVP), with 1 min intervals between individual crosslinking sessions. Harvested cells were pelleted
and placed in ice, followed by IP or flash freezing in liquid nitrogen and storage at 80C.
Protein G Dynabeads preparation
50 mL beads (bed volume; 1.5 mg; per cells’ aliquot obtained from 145-mm dish) were washed 2x in 1ml PBS/0.1% Tween20. There-
after the beads were suspended in 50 mL PBS/Tween plus 10 mL M2 mouse monoclonal anti-FLAG antibodies (10 mg; Sigma), fol-
lowed by incubation at room temperature for 30-45 min with occasional pipetting. The unbound antibody was then removed and
the beads washed 2x in 1ml PBS/Tween supplemented with 10 ng/ml E. coli tRNA (Roche) for 15min. Finally, the beads were sus-
pended in 100 mL PBS/Tween plus 10 ng/ml tRNA and added to clear lysates aliquots. Note the beads for all experimental conditions
within one experimental set were prepared in batch.
IP with FLAG-TUT7 (and MBP-TUT7 as the control)
The cells (of one 145-mm dish) were lysed in 1 mL Lysis buffer (50 mM Tris-HCl, 8.0; 50 mM NaCl; 0.5% Igepal CA-630 (NP40 sub-
stitute; Sigma); 5mMEDTA supplementedwith a protease inhibitorsmix) by pipetting 20 times in ice, followed by 10min incubation in
ice and 5 cycles of sonication (at 4C; 30 s on, 30 s off; H setting in a Diagenode Bioruptor sonicator). Crude lysates were centrifuged
at 500 rcf., 4C in 2 mL protein low-bind tubes (Eppendorf). Cleared lysates were mixed with the protein G-M2 anti-FLAG antibodies-
coupled Dynabeads in protein low-bind tubes, followed by head-over-tail rotation at6-8C for 2h. Thereafter, the lysates (unbound
material) were removed and the beads were washed 2x with 1ml 1x Lysis buffer, followed by 4x in Stringent Washing Buffer (50 mM
Tris-HCl, 8.0; 1 M NaCl, 0.1% Igepal CA-630; 1.3 M urea; 5 mM EDTA supplemented with a protease inhibitor mix) and 2x in Lysis
buffer. Each washing was performed for 8-10min at8C.Washing volumes were removed efficiently while beads were gathered on
a magnetic stand using a vacuum pump with disposable tips. For the last washing the beads were transferred to new tubes. There-
after, enriched proteins and RNAs were released from the beads by heating at 80C for 3 min twice with 75 mL Release Buffer (2%
SDS; 20mMEDTA; 50 mMTris-HCl, 8.0; 10 mMDTT; 20% glycerol; 10 ng/ml E. coli tRNA). 130 mL were taken for RNA extraction. To
uncouple covalently cross-linked RNAand protein themixwas supplementedwith 20 ng proteinase K (USB) and incubated for 30min
at 37C followed by standard phenol-chloroform-isoamyl alcohol extraction, TURBODNase treatment and final purification on RNA-
specified silica columns (A&A Biotechnology). Remaining released materials were treated with 50U viscolase for 10 min at 37C (to
uncouple covalently linked RNA and proteins; A&A Biotechnology) separated on SDS-PAGE and stained with silver or transferred to
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Estimation of LINE-1 and GAPDH mRNA enrichment levels
All of the retrieved RNA was reverse transcribed with Superscript III (according to the manufacturer’s recommendations). The cDNA
was used for qPCR with Taq-Man probes as described below in the methods applied to estimate steady-state levels and stabilities
of mRNAs.
Related to Figure 5E. Enrichment of either LINE-1 or GAPDH mRNA in FLAG-TUT7 co-IP versus control MBP-TUT7
co-IP (after transfection with non-targeting control siRNA) were calculated by using the following formula:
2-(Ct(FLAG-TUT7 co-IP) – Ct(MBP-TUT7 co-IP)); where Ct is an average Ct of 3 technical qPCR reactions of either LINE-1 megfpI or GAPDH.
Related to Figure 5F. LINE-1 and GAPDH levels in FLAG-TUT7 co-IPs from cells transfected with either control non-targeting
siRNA or siRNA for MOV10 depletion were related by using the following formula: 2-(Ct(LINE-1) – Ct(GAPDH)) and normalizing median
reported for all control co-IPs (without MOV10 depletion) to 1.
Enrichments were calculated using methods described by Livak and Schmittgen (2001). Statistics were calculated using a non-
parametric two-tailed Mann-Whitney test (GraphPad Prism package).
Retrotransposition assay –megfpI
Transfection and culture conditions
Related to Figure 1B. 293T cells were seeded in 6-well plates at 0.3x106 cells per well. At20h after seeding, cells from a single well in
2 mL medium were transfected with 0.75 mg of 99 PUR RPS EGFP (or 99 PUR JM111 EGFP as an internal negative control) plasmid
and 1.5 mg of pZWplasmids encodingMOV10, TUT4 or TUT7, or catalytically inactivemutant versions of TUT4 or TUT7 (all with N-ter-
minal maltose binding protein tags, MBP) or only MBP (internal positive control), using 7 mL Lipofectamine 2000 (ThermoFisher Sci-
entific) in 300 mL OPTI-MEM (GIBCO) per well. The next day, the medium was exchanged for medium supplemented with 1 mg/ml
puromycin (Invitrogen) to select for cells carrying the L1 reporter plasmids. Cells were further selected for 3 days. The medium
was then exchanged and the cells were analyzed by flow cytometry on the following day (4 days post-transfection). LINE-1 retro-
transposition restriction was also observed when TUTases or MOV10 were tagged with N-terminal FLAG or mCherry tags.
Related to Figure 1C. 293T cells were seeded in 6-well plates at 0.3x106 cells per well. At20h after seeding, cells in a single well in
2mLmediumwere transfected with 1 mg 99 PURRPS EGFP (or 99 PUR JM111 EGFP for negative controls) LINE-1 retrotransposition
reporter plasmids and 50 pmol (in total) siRNAs targeting TUT4, TUT7,MOV10 or TUT1mRNAs or control non-targeting siRNA (high
GC content control siRNA from Invitrogen) as described above. Cells were selected for 3 days. The medium was exchanged for me-
dium lacking puromycin and the cells were analyzed by flow-cytometry 4 days post-transfection.
Duplicate to triplicate transfections were performed for each condition in a single experiment. Two or three experiments included
up to at least 6 biological replicates. We generally observed 1%–4% of EGFP-positive cells in the control conditions (MBP). We did
not find selection with puromycin critical however it prevented excessive proliferation of cells within the 4 days between transfection
and FC analysis.
Related to Figure 3B. 293T cells were seeded in 12-well plates at100-150x103 cells per well. Next day, the cells were transfected
with 0.5 mg pZW-L1RP-x reporters (where x specifies the pre-designed 30 end) using 3 mL Lipofectamine 2000 (ThermoFisher Scien-
tific) in 200 mL OPTI-MEM (GIBCO). Retrotransposition was allowed to occur for 80h followed by FC analysis as described above.
Selection of cells was not carried out. On average 2%–4% cells transfected with th 26A reporter were EGFP positive at the day of
analysis.
Flow cytometry – retrotransposition assays
Cells were detached from the wells of the multiwell plates by trypsinization and were suspended in medium containing FBS to stop
trypsin activity before centrifugation at 350 rcf. for 3min. Themediumwas removed and the cells were suspended in 1mLPBS. EGFP
signals weremeasured using an AttuneNxT instrument (Thermo Fisher Scientific) equippedwith 488 nmand 561 nm light beams. The
data were analyzed using software provided with the instrument. To gate EGFP+ cells, we first used cells transfected with 99 PUR
JM111 EGFP containing a mutated LINE-1 (L1-ORF1p, R261A/R262A), which abolish retrotransposition (Moran, et al., 1996). The
gates were adjusted such that % 0.025% cells transfected with 99 PUR JM111 EGFP fell within the EGFP+ gate. At least
200x103 singlet cells were analyzed for each condition. Medians were calculated for all biological replicates and themedians for pos-
itive control samples were arbitrarily set as 1. Statistical significance was calculated using ANOVA and Tukey’s multiple comparison
test for all pairs.
Retrotransposition assay –mneoI
HeLa-HA cells were seeded in 6-well plates at 0.12-0.5x106 cells per well. At20h after seeding, cells from a single well in 2 mL me-
diumwere transfected with 50 pmol (in total) siRNA targeting TUT4, TUT7, orMOV10 or control siRNA (high or lowGC content control
siRNA from Invitrogen) using 3-5 mL Lipofectamine RNAiMAX (ThermoFisher Scientific) in 300 mL OPTI-MEM (GIBCO). On the
following day, the medium was exchanged and the cells were allowed to propagate for 48h before subsequent transfection with
1 mg of either JM101/L1.3 mneoI plasmid or 99 PUR RPS EGFP (for negative controls) LINE-1 retrotransposition reporter plasmids.
The day after transfection, the medium was exchanged and the cells were allowed to propagate for 4 days with a change of medium
every 2 days. Thereafter, the cells were incubated for 12-18 days with medium supplemented with 600 mg/ml G-418 (Invitrogen) to
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violet and counted. Six independent experiments were performed (some in duplicates). The number of colonies in each experiment
and experimental condition was normalized to respective controls assuming that the mean retrotransposition rate in the control is 1.
Analyses of L1-ORF1p and L1-ORF2p translation
Plasmids encoding active LINE-1s: (i) JM101/L1.3-O1EGFP-O2cherry, where L1-ORF1 has been fused with the EGFP cDNA
and where L1-ORF2 has been fused with the mCherry cDNA, (ii) pZW-L1RP-O1-mCh encoding L1-ORF1p-mCherry and (iii)
pZW-L1RP-O2-G encoding L1-ORF2p-EGFP were used to estimate translation efficiency.
293T cells were co-transfected with either of the above plasmids and pZW plasmids for overexpression of N-terminal tagged pro-
teins as described in ‘‘Retrotransposition assay – megfpI.’’
Cells were analyzed by flow cytometry 48 h post-transfection. For analyses of L1-ORF1p and/or L1-ORF2p translation alone, only
those cells displaying fluorescent signals above that of background levels determined for non-transfected control cells were used.
Median intensities were calculated for biological replicates and arbitrarily set to 1 for MBP-expressing cells (controls). Statistical sig-
nificance was calculated as described in the section ‘‘Flow cytometry – retrotransposition assays.’’
RNA isolation
Total RNA was isolated from cells using 1 mL TRI-reagent (Sigma) (Chomczynski and Sacchi, 1987) per well of 6-well plates accord-
ing to themanufacturer’s instructions. After RNA recovery, the RNA pellets were suspended in100 mL TNES buffer (50mMTris-HCl
pH 8, 100 mM NaCl, 10 mM EDTA, 1% SDS) supplemented with 20 ng/ml proteinase K (USB) and incubated for 15 min at 37C to
remove contaminating proteins. The material was then subjected to two phenol-chloroform extractions. To remove DNA contamina-
tion, 5-10 mg input RNA used for RNA-seq and 30 RACE-seq was additionally treated for 30 min at 37C with 2 mL Ambion TURBO
DNase (ThermoFisher Scientific) in 50 ml. RNA was then purified by either two sequential phenol-chloroform extractions and ethanol
precipitation or with Clean-Up RNA concentrator silica RNA-binding columns (A&A Biotechnology).
Northern blotting
Cell culture and RNA retrieval
Related to Figure 4A. 293T cells were seeded in 6-well plates at 0.5x106 cells per well. At 20h post-seeding, cells in a single well in
2 mLmediumwere transfected with 0.75 mg JM101/L1.3 nomarker and 1.5 mg pZW plasmids: empty (p0 described as pKK-NoTag in
Szczesny et al. [2018]), or encoding EGFP, mCherry, MBP, or MOV10, TUT4, TUT7 or TUT4 and TUT7 catalytically inactive mutant
versions tagged with N-terminal MBP using 7 mL Lipofectamine 2000 (ThermoFisher Scientific) in 300 mL OPTI-MEM (GIBCO) per
single well. At 30h post-transfection, the medium was removed and RNA was extracted using 1 mL TRI-reagent per well (as
described in ‘‘RNA isolation’’).
Related to Figure S4A. Total, TURBO DNase (Ambion)-treated RNA from HEK293 FLP-IN T-Rex, 293T, PA-1 and HeLa-HA cells
was used in a poly(A) mRNA selecting protocol with the Ambion’s Poly(A)Purist MAG kit according to the manufacturer’s
recommendations.
RNA separation in denaturing agarose gels
To visualize long RNA with high resolution, we used the protocol described by Mansour and Pestov (2013). Briefly, RNAs were sepa-
rated in 153 20 cm1%agarose gels with 0.45M formaldehyde in TT buffer for 4-5h at 70 V until the xylene cyanol dye front waswithin
0.5 cm of the gel margin. Gel electrophoresis capillary transfer to Amersham Hybond N+ nylon positively charged membranes was
then immediately performedO/N at RT in 20x SSC. The blots were rinsed in water and RNAwas fixed to themembrane by 254 nmUV
crosslinking using a CL-1000 crosslinker (UVP) with the auto crosslink function (120 mJ/cm2). The membranes were stained with
methylene blue and the staining was digitized. The membranes were then preincubated in PerfectHyb hybrydization buffer (Sigma)
for at least 1h at 65C.
Probe production
We used ssDNA probes randomly labeled with a32P (dATP). For templates, we used PCR amplicons generated on the template of the
99 PURRPS EGFP plasmid and the primers L1_seq7 (forward; see Table S1) and ORF2_rev1 (reverse) to obtain a 497 bp fragment of
the L1-ORF2 30 region. The PCR amplicon (100 ng) was used in a custom linear amplification using only a single primer,
SONDA_ORF2 (reverse), together wtih 50 mM dCTP/dGTP/dTTP and a32P dATP 1 mM in Phusion HF buffer using Phusion HF
polymerase (Thermo Scientific). A total of 25 cycles were used to generate a 154 bp probe. Analogous probes were prepared for
GAPDH using the primers GAPDH_qP_f1 (forward) and GAPDH_qP_r2 (reverse) to yield a 930 bp dsDNA fragment and
GAPDH_qP_r1 (reverse) to generate the ssDNA probe.
All probeswere separated from template dsDNA and shorter products using 6%denaturing PAGE. Full-length probeswere cut-out
of the gel, eluted in 300 mM sodium acetate/2 mM EDTA/5%phenol+chloroform+isoamyl alcohol mixture (25:24:1) overnight and
precipitated with ethanol as described in Razew et al. (2018).
Hybridization conditions
Blots were incubated with0.5-1x106 cps/ml probes in5-10 mL PerfectHyb hybridization buffer (Sigma) for 24h at 65C with con-
stant head-over-tail rotation. Blots were washed 3 times with 0.5x SSC/0.1% SDS for 20 min at 65C before drying and exposure to
Fuji 32P screens. The screens were scanned using a Fuji PhosphorImager (FLA7000).e10 Cell 175, 1537–1548.e1–e17, September 6, 2018
RNA-seq
Cell culture and RNA retrieval
Triplicate biological samples were prepared for each tested condition.
HEK293 FLP-In T-Rex cells were cultured (and transfected) in 6-well format as decribed above for retrotransposition assays.
For overexpression conditions: HEK293 FLP-In T-Rex stable cell lines expressing EGFP-TUT4, EGFP-TUT7 were cultured for 48h
in the presence of 100 ng/ml tetracycline or in its absence. Similarly, HEK293 FLP-In T-Rex cells were transfected with pZW-EGFP-
MOV10 plasmid for MOV10 overexpression and cultured with or without tetracycline for 48h before harvest.
For depletion conditions in HEK293 FLP-In T-Rex: cells were transfected with 50 pmoles respective siRNAs using 5 mL Lipofect-
amine RNAiMAX (Invitrogen) according to the manufacturer’s recommendations and cultured for 68h prior to harvesting.
For depletion conditions in PA-1: cells were transfected with siRNAs as described in ‘‘Northern blotting.’’ After 3 days, the cells
were trypsinized and transferred into new 6-well plates at 0.2x106 cells per well, followed by another identical transfection. Finally,
6 days after the first siRNA transfection the cells were used to isolate total RNA as described above. A portion (1/3 volume inmedia) of
the trypsinized cells was used for protein retrieval for western blotting validation of protein depletion. RNA was treated with Ambion
TURBO DNase (ThermoFisher Scientific) according to the manufacturer’s recommendations.
RNA-seq library preparation
Following DNase treatment, all RNA samples were supplemented with equal amounts of ERCCRNA spike-in mix (Thermo Fisher Sci-
entific) followed by depletion of rRNA using a Ribo-Zero H/R/M Kit (Epicenter) according to themanufacturer’s protocol. Strand-spe-
cific RNA libraries were prepared in triplicate using a KAPA Stranded RNA-seq Library Preparation Kit for Illumina platforms (KAPA
Biosystems) according to the manufacturer’s protocol that included RNA fragmentation for 8 min at 95C and 700 mM adapters for
amplification. We used 7 cycles of amplification to generate the libraries, which were analyzed by capillary electrophoresis using a
Bioanalyzer 2100 (Agilent). The libraries contained 250 bp inserts.
RNA-seq library sequencing
The libraries were sequenced using Illumina NextSeq500 (75-nt paired-end mode) and HiSeq2500 (100-nt paired-end mode)
sequencing platform to an average number of 20x106 reads per library. Details in the online supporting material.
LINE-1 s differential expression
Reads were mapped against the human genome (ver. hg38) using STAR (Dobin et al., 2013) and counted using TEtranscripts
(Jin et al., 2015) and –mode unique settings, with Gencode v27 basic for gene and hg38_rmsk_TE.gtf downloaded from http://
labshare.cshl.edu/shares/mhammelllab/www-data/TEToolkit/ for repetitive elements annotation. Differential expression analysis
was performed using DESeq2. For the purpose of statistical analysis counts for all human-specific LINE1 sequences were summed
and treated as single. For the purpose of Figures 4F, 4G, and S4F experimental samples were normalized to controls using a normal-
ized counts mean across all control replicates.
Rapid Amplification of 30 cDNA ends with high throughput sequencing (30 RACE-seq)
Cell culture and RNA retrieval
At least 3 biological replicates were prepared for each tested condition.
Tests of the effects of either protein overexpression or depletion were performed in both HEK293 FLP-In T-Rex cells. The trans-
fection conditions were as described above in ‘‘Retrotransposition assay – megfpI.’’
PA-1 cells were used to assess the effects of TUTases or MOV10 depletion on LINE-1 30 ends. Cells were transfected as described
above in ‘‘RNA-seq.’’
To test genome-encoded LINE-1 mRNA, wild-type, unperturbed PA-1, H9 and NPC cells were cultured as described above.
Mouse testis tissue was acquired as described above.
RNA was isolated as described above.
Splint-ligation of long spike-in ssDNA
In the original TAIL-seq paper (Chang et al., 2014), full-length spike-in sequences used in TAIL-seq sequencing for poly(A) length esti-
mation were generated by PCR using a long ssDNA template. We prepared spike-ins as described by Cheng et al., 2014. In this case,
however, long-A spike-ins (64 As and to a far lesser extend 32As) but not the short-A spike-ins tended to become shortened in PCR.
Thus we ordered full-length ssDNA spike-ins to avoid amplification. Spike-ins having 0, 8, 16 and 32 consecutive adenines could be
ordered as single synthetic DNAs whereas spike-in comprising 64 consecutive adenines could not be synthesized in this way. We
thus ordered 50 and phosphorylated 30 regions of these spike-in (see Key Resources Table) for use in splint ligations. The reaction
comprised 200 pmol 50 fragment, 200 pmol splint DNA and 300 pmol 30 phosphorylated fragment in 10 mM Tris-HCl pH 8 and
20mMNaCl in 33 ml. The reaction was heated to 80C for 5 min, slowly cooled to RT, and combined with 4 mL and 3 mL T4 DNA ligase
buffer and enzyme (NEB), respectively. The reaction was incubated at RT (22C) for 2h and then mixed with formamide loading dye.
Ligated full-length ssDNA spike-in were separated from 50 and 30 fragments and the splint in 6% denaturing PAGE and purified. The
ligation efficiency was 50%–70%.
30 RACE-seq library preparation
Total RNA acquired from either whole cells or testis or from cytoplasmic and nuclear cell compartments was treated with Ambion
TURBO DNase (ThermoFisher Scientific) according to the manufacturer’s recommendations and as described above. RNA
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barcoded with a 15N sequence). The reactions were carried out in 20 mL with 1x T4 RNA ligase 2 truncated buffer (NEB) supple-
mented with PEG-8000 at 10% final concentration, 0.25 U/ml RiboLock inhibitor (Thermo Fisher Scientific), 3 pmol of the 50 FAM-
labeled 44-mer oligonucleotide RNA44 (Future Synthesis) and 300 U T4 RNA ligase 2 truncated (NEB) for 18h at 18C. To assess
ligation efficiency, 1/10 of the sample was loaded onto 10% denaturing PAGE to separate free and RA3_15N-ligated RNA44. The
gels were scanned using a FLA-7000 apparatus (GE Healthcare). We assessed the ligation efficiency of RNA44 and RA3_15N to
be at least 80% for all samples. The remaining sample was mixed with 18 mL Agencourt AMPure XP magnetic beads (Beckman
Coulter) and the ligated RNAs were separated from non-ligated adapters and short (< 100 nt/bp) RNA/DNA fragments according
to the manufacturer’s protocol. RNA ligated to RA3_15N was released from the beads with 20 mL water.
The samples were thenmixed with 100 pmol RNA PCR Index Primers (Tru-Seq Illumina) that each contained a barcode specific for
the sample (48 indexes available). The primers base-paired with the 30 end of the RA3_15N adaptor to preserve the individual tran-
script barcoding (15 degenerate nucleotides). The samples were then reverse-transcribed in 20 mL using 200 U (1 ml) Super Script III
reverse transcriptase (Thermo Fisher Scientific) according to the manufacturer’s protocol. After incubating RNA-RA3_15N with the
primers and dNTPs (0.2 mM) at 65C for 5min, the samples were cooled to 55C for 5min and placed on ice. Buffers were then added,
followed by addition of SSIII and incubation at 55C for 1 min and 45min at 45C. The enzymes were then denatured by incubating at
75C for 15 min. The cDNAs were purified from the excess primers, fragmented RNA and reaction buffers using Agencourt AMPure
XP beads as described above.
30 RACE-seq libraries were generated using a nested PCR approach for reporter plasmid-encoded and endogenous genome-en-
coded LINE-1mRNAs. Libraries for ACTB, GAPDH, PABPC4 and SOGA2mRNAswere prepared as controls. For each sample, 1/4 of
the cDNA was used in a 20 mL PCR reaction with mRNA-specific outer primers (see Table S1) at 0.4 mM and 0.3 mM of a universal
reverse primer RPuni (denoted uni rev in Figure S7), which is complementary to the extreme 30 region of all RNA PCR Index Primers.
Phusion HF enzyme and buffers (Thermo Fisher Scientific) were used according to the manufacturer’s recommendations. Routinely,
20 PCR cycles were performed with a 12 s elongation at 70C. The PCR1 amplicons were purified from excess unused primers, frag-
mented RNA and reaction buffers using Agencourt AMPure XP beads as described above.
A second PCR (PCR2) was performed using purified products from the first PCR (PCR1) as templates in a 25 mL reaction volume.
Outer primers specific for the mRNAs were used as specified in Table S1 at 0.36 mM and RPuni at 0.4 mM. The other reaction con-
ditions were as for PCR1. PCR2 products were purified twice using Agencourt AMPure XP beads. Following purification, the libraries
were eluted in 20 mL and quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Most of the libraries were within
10-30 ng/ml. The libraries were diluted to 3-5 ng/ml and analyzed by capillary electrophoresis using a Bioanalyzer 2100 (Agilent). Most
libraries were 280-300 bp long (after subtracting 120 bp adaptor sequences). Libraries and spike-in ssDNA sequences (used to
estimate poly(A) length, synthesized as ‘‘ultramers’’ by IDT) were quantified using qPCR with primers P5 and P7R and a Platinum
qPCR kit (Thermo Fisher Scientific).
30 RACE-seq library sequencing
30 RACE-seq libraries were sequenced on Illumina MiSeq, using V3 chemistry, with settings forcing storage of raw intensity files (cif
files). To overcome the limitation of maximum number of individual libraries sequenced in single sequencing run we pooled libraries
targeting different transcripts and restored them in the further analysis steps using unique primer sequences. All libraries were
sequenced with the pair-end settings, with read lengths 300+300 (with the exception of one experiment, where 100+150 read lengths
were used). Special full-length spike-in ssDNA (references for poly(A) length) were included to produce 150x103 reads per single
spike-in.
30 RACE-seq library cloning
Related to Figure S2E. Selected libraries were also cloned into pCR-Blunt II-TOPO (Invitrogen) or pJET1.2/blunt (Thermo Fisher Sci-
entific) according to the manufacturer’s recommendations. Plasmid mini (A&A Biotechnology) was used for plasmid preparation.
Clones were digested with enzymes flanking the insert and selected clones were sequenced using standard Sanger sequencing.
30 RACE-seq data analysis
Graph presenting the flow of the analysis is presented in Figure S7B. Raw sequencing data (containing cif intensity files) were pro-
cessed using tailseeker 3.17 (https://github.com/hyeshik/tailseeker), to produce fastq output and get information about the length of
A-tails (and possible additions at the 30end of the tail). Output files were demultiplexed by primer sequences using sabre (https://
github.com/najoshi/sabre, modified to leave primer sequences from the output), allowing maximum 2 mismatches in the primer
sequence. Resulting reads were then further processed using a set of in-house prepared scripts to get detailed information regarding
30 ends of analyzed transcripts. For libraries targeting LINE1 reporter (or control transcripts:ACTB,GAPDH,PABPC4 orSOGA2) both
50 (R5 – notation based on the tailseeker3 output) as well as 30 (R3) reads were mapped to the respective sequences using bowtie2
(Langmead and Salzberg, 2012), with –very-sensitive-local setting to allow for soft-clipping of non-templated nucleotides. In the case
of libraries targeting endogenous LINE1 sequences Repeatmasker (Smit, AFA, Hubley, R &Green, P. RepeatMasker Open-4.0. 2013-
2015, http://www.repeatmasker.org) was used over both R5 and R3 reads, with settings ‘‘-norna -nolow -qq -div 10’’ and human
repeats library filtered to contain LINE1 sequences only, or mouse specific database in case of murine samples. Part of sequences
which were not assigned to any LINE1 sequence were treated as non-templated (clipped) as in the case of reporter LINE1 sequences
and extracted for further analysis. For all subsequent steps only pairs in which at least one readwas identified as coming from desired
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Next, we analyzed 30 end types of tails present in analyzed samples and the rate of uridylation. All pairs for which tailseeker iden-
tified any tail were included in the analysis without any modification. In the other case we used non-templated nucleotides to further
classify such reads. As we expected short fragments due to localization of RACE primers, only reads containing tailseq-delimiter
sequence CTGAC in non-templated fragment of R5 were considered for analysis. Any nucleotides preceding the delimiter were
treated as a possible tail. If a non-templated fragment didn’t contain any nucleotides before CTGAC such reads were excluded
from the analysis. In the case of experiment, where R5 read was much shorter (50nt), if we were able to locate CTGAC delimiter
sequence in R5 non-templated fragment, preceding nucleotides were treated as a tail, otherwise sequence clipped from the R3
read was treated as a possible tail.
All possible tails were then grouped into classes based on their nucleotide composition: (i) A-only tails ii) AU tails (A tail with addi-
tional U); (iii) U-only tails; (iv) no tail – when no tail was detected and (v) other (no falling into any of mentioned classes). The latter were
excluded from the analysis as they are possible artifacts of the nested PCR protocol used for library generation.
Uridylation frequency was calculated as fraction of AU and U-only tails compared to all classified.
30 RACE-seq statistics
For multiple group comparisons, when normality assumptions were met, we used one-way ANOVA and Tukey’s post hoc test.
Assessment of LINE-1 mRNA steady-state levels and stabilities by RT-qPCR
Estimation of LINE-1 mRNA steady-state levels
Related to Figure 3B. 293T cells were plated at 120x103 cells per well of a 12-well plate. Next day the cells in a single were transfected
with 0.5 mg pZW-L1RP-megfpI-xyz-TRL (where xyz is either of: 19A, 19A3U, 26A, 26A2U, 26A4U, 26A6U, 26A26U, 7U, 26U) and 3 mL
Lipofectamine 2000 (Invitrogen) in 200 mL OPTI-MEM (GIBCO). Triplicate to quadruplicate transfections were done for a single re-
porter in a single experiment (3 experiments in total). Cells were harvested 36-40h post-transfection and RNA isolated using TRI
reagent and as described in the below paragraph.
Related to Figures 4 and S4. RNA was retrieved as for RNA-seq. Four to six biological replicates were analyzed.
Estimation of reporter LINE-1 mRNA stability – transfections and RNA retrieval
293T cells were plated at 360x103 cells per well of a 6-well plate. Next day the cells in a single well were co-transfectedwith 1 mg pZW-
L1RP-megfpI and 1 mg pZW plasmid encoding either MBP, MBP-TUT4, MBP-TUT7, MBP-MOV10 (or FLAG-tagged versions, but
TUT4 that does not express well with N’ FLAG) and 6 mL Lipofectamine 2000 (Invitrogen). 8h later cells from 1 well of a 6-well plate
were trypsinized and reseeded onto 6 wells of a 24-well plate. After additional 12h actinomycin D was added in time intervals to
expose the cells to the chemical for 6, 4, 3, 2, 1h and a single well was kept without actinomycin D addition. Themediumwas removed
and the cells were covered with 0.5 mL TRI reagent (Sigma). RNA was isolated using extraction with chloroform as described in the
manufacturer’s procedures and additional phenol-chloroform extraction. RNA was measured and 5 mg treated with 2 mL TURBO
DNase (Ambion) according to the manufacturer’s procedure for 1h. Following enzymatic DNA removal RNA was purified from the
reaction mixture using Clean-Up RNA Concentrator silica columns (A&A Biotechnology), eluted with 40 mL water and concentration
estimated by UV spectroscopy. Six independent biological replicates were performed.
RT-qPCR
Reverse transcription of 0.2-1 mg of RNAwas performedwith SuperScript III (Invitrogen) according to the attached protocol and using
priming with 50 ng of random primers (Invitrogen). Obtained cDNA was subjected to qPCR experiments in 20x final dilution. Two
different approaches were applied. Endogenous LINE1 and LINE1 reporter transcripts were detected in TaqMan type assay (Applied
Biosystems, TaqMan Fast Advanced Master Mix and primers and probe with FAM dye) in one reaction with probes for detection of
GAPDH transcripts (Applied Biosystems, TaqMan Gene Expression Assay, 4448490, probe with VIC dye). Custom oligonucleotides
sequences were as follows, for detection of LINE1 reporter: forward primer TAQMAN_EGFPI_2_FOR, reverse primer TAQMAN_
EGFPI_2_REV, probe TAQMAN_EGFPI_2_PROBE (see Table S1).
For detection of endogenous L1-Ta mRNA primers and probe were adapted from Coufal et al. (2009): forward primer Coufal_for
(see Table S1), reverse primer Coufal_rev, probe Coufal_probe.
MYC transcripts levels were detected using standard qPCR approach and Platinum SYBR Green qPCR SuperMix-UDG (Invitro-
gen) with 0.2 mM primers: forward primer TTCGCAACTATGTGTTCGCG (U6ChF), reverse primer AAAACGGTTCATCCT
TATGC (U6ChR).
Amplification and data acquisition was conducted in LightCycler 480 (Roche) using standard temperature schema and reaction
compositions proposed by the qPCR reagents manufacturers.
LINE-1 Amplification Protocol
LINE-1 amplification protocol (LEAP) analysis was performed on the basis of the concept described by Kulpa and Moran (2006) with
modifications.
Briefly, three 145-mm dishes were each seeded with 3x106 HEK293T cells. Fourteen hours after seeding, the cells in 25 mL me-
dium were transfected with 14 mg of pZW-L1-26A-TRL, pZW-L1-26U-TRL or pZW-L1-26A26U-TRL using 60 mL Lipofectamine in
5 mL OPTI-MEM (GIBCO) as per the manufacturer’s recommendations. Around 40h after transfection, the cells reached90% con-
fluency and were harvested by scraping into PBS and centrifuging at 2,800 rcf. for 7 min at 4C. The cell pellets were then suspended
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cells were lysed by pipetting several times, incubated on ice for 10min and centrifuged at 4,000 rcf. for 2min at 4C. Then, 300 mLwas
taken from each sample and centrifuged again as described above. About 220 mL was loaded onto a sucrose cushion in 20 mM Tris-
HCl pH 7.5, 80mMNaCl, 5 mMMgCl2, 1 mMDTT supplemented with EDTA-free protease inhibitors at 25
C (top 250 mL 8% sucrose,
bottom 800 mL 17% sucrose) in TFT-80.2 tubes and spun at 58,000 rpm for 2h at 4C in a TFT-80.2 rotor (Thermo Fisher Scientific).
The transparent to yellowish pellets,3mm in diameter, were suspended by pipetting in 160 mL (each) 0.1x PBS, 50%glycerol, 5mM
DTT supplemented with EDTA-free protease inhibitors. A portion of this sample was flash frozen in liquid nitrogen and stored at
80C for RT-PCR.
Eight reverse transcription reactions in 20 mL that included 1 mL suspended RNPs, 0.2 mM reverse primer LEAP_12T or LEAP_12A,
0.3 mMdNTPs and buffers provided with the Super Script III reverse transcriptase (First Strand buffer, 250mMTris-HCl pH 8.3 at RT,
375 mM KCl, 15 mMMgCl2 supplemented with DTT to 5 mM) were prepared. Reactions were carried out at 37
C for 1h followed by
protein denaturation at 75C for 15min. The cDNAwas purified using 1 volume Agencourt AMPure XP beads as described above and
eluted with 20 mL water.
The purified cDNA (1 ml) was used in a standard PCR reaction in 25 mL total volume with Phusion HF polymerase and buffers
(Thermo Fisher Scientific) and 0.2 mM both forward L13UTRef primer and LEAP_rev reverse primer. Amplification was performed
in 35 amplification cycles. 10 mL of the reactions were separated in 1% EtBr-agarose gel.
Recombinant protein production
TUT7 was expressed in FreeStyle 293-F cells (Invitrogen) that were cultured to a density of 13 106 cells/ml in five 30 mL aliquots of
FreeStyle 293 Expression Medium (GIBCO). The cells were transfected using 90 mg linear PEI at 1 mg/ml (MW = 25,000; Polysciences,
Inc.) and 30 mg of pZW-EGFP-ZCCHC6 for EGFP-TEV-TUT7 expression. Following transfection, the cells were cultured for 48h at
37C, 5% CO2, with constant rocking at 120 rpm. Flow cytometry of a small fraction of the pZW-EGFP-ZCCHC6-transfected and
non-transfected cells showed that 25%–35% of cells expressed EGFP-TUT7 proteins over that of background levels. The cells
were then centrifuged for 5 min at 500 g and the resulting cell pellet was suspended in 5 mL Buffer 1 (20 mM Tris-HCl pH 8,
500 mM NaCl, 0.1% Triton X-100, 100 U viscolase nuclease (A&A Biotechnology) and protease inhibitors). The mixture was rotated
head-over-tail at 10C for 15 min and then sonicated at 10C for 30 min using a Bioruptor sonicator (Diagenode) operating in the
heavy duty setting with 15 s pulses followed by 45 s pauses. The lysate was cleared by centrifugation at 12,000 rcf. at 4C for
20 min. The resulting supernatant was bound to magnetic beads (CNBr-activated SepFast Mag4F, Biotoolomics) coupled to an
anti-EGFP nanobody (home-made) for 2h at 10C with head-over-tail rotation. The beads were then washed with 40 bed volumes
Buffer 1. TUT7 was released from the beads by TEV protease (home-made) digestion in 300 mL Buffer 1 supplemented with 10 mg
TEV protease for 12h. The released and bead-retained proteins were analyzed by SDS-PAGE and Coomassie Brilliant Blue staining.
Aliquots were supplemented with glycerol to 20%, frozen and stored at 80C.
MOV10 WT and MOV10 K530A mutant (Gregersen et al., 2014) were prepared similarly to what is decribed above except that an
N-terminal MBP tag was used (pZW-MBP-MOV10 or pZW-MBP-MOV10_K530A plasmids) and affinity chromatography was carried
out with amylose resin (NEB).
L1-ORF1pwas produced inEscherichia coli. The full-length L1-ORF1CDSwas amplified using the 99 PURRPSEGFPplasmid as a
template and was cloned into the pET28 expression vector, with a C-terminal 6xHis tag. The plasmid was then transformed into
BL21-RIL cells and an aliquot was used to inoculate LB supplemented with kanamycin (50 mg/ml) and chloramphenicol
(37.5 mg/ml). The cells were grown for 12h at 37C with constant rocking (150 rpm). An inoculum from this culture was then used
to start a 1 L culture in an autoinducing medium (AIM-Formedium) and the culture was continued for 48h at 18Cwith constant rock-
ing. The cells were harvested by centrifugation and the cell pellet was suspended in 150 mL Buffer 1 (20 mM Tris-HCl pH 8, 500 mM
NaCl, 10 mM imidazole supplemented with protease inhibitors (Roche EDTA-free) and 50 mg/ml lysozyme). The cells were lysed with
the Emulsiflex for 15 min following themanufacturer’s guidelines. The lysate was cleared by centrifugation at 37,000 rpm in a Thermo
FL37 8 3 100 rotor at 4C for 45 min. Recombinant L1-ORF1p was bound to a 5 mL NiNTA FastFlow column (QIAGEN) using Akta
Xpress, and the column was washed with 20 column-volumes of Buffer 1 and two column volumes of Buffer 2 (20 mM Tris-HCl pH 8,
1MNaCl). ORF1was eluted with Buffer 3 (20mMTris-HCl pH 8, 500mMNaCl, 300mM imidazole). Aliquots of the collected fractions
were analyzed by SDS-PAGE and Coomassie Brilliant Blue staining. Those fractions containing L1-ORF1p were diluted to produce
100 mM NaCl and underwent a final purification on a RESOURCE Q column (GE Healthcare) and gel-filtration on a size-exclusion
HiLoad Superdex-200 column (GE Healthcare). The purified protein was analyzed by SDS-PAGE and the concentration was deter-
mined using a Nanodrop apparatus at 280 nm and the respective molar extinction coefficient. Samples were supplemented with
glycerol to 10%, frozen and stored at 80C.
ScPRP2was purified as described inWarkocki et al. (2009). The full length PRP2 genewas PCR amplified from a genomic library of
S. cerevisiae (Strain W303A) and ligated into pET21a (Novagen), thus fusing the protein to the C-terminal hexahistidine tag. The
plasmid was transformed into E. coli strain Rossetta II (Novagen) by heat-shock procedure. Cultures were grown in 1 L of an auto
inducing media, containing amipicillin, incubated at 17C for 20 or 48 h, respectively. Cells were harvested by centrifugation, washed
and the pellets stored at –80C. Prp2 protein purification was performed at 4C. The cell pellets were suspended by vortexing in 5ml
lysis buffer (50 mM HEPES NaOH pH 7.5, 600 mM NaCl, 2 mM b-mercaptoethanol (b-ME), 20 mM Imidazol, 10% glycerol) per 1 g
cells and lysed with a fluidiser system at 80 psi 6 times (Microfluidics). Insoluble material was removed by centrifugation for 40 min at
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with lysis buffers, using the A¨kta Prime system (GE Healthcare). Contaminants were removed (His tagged proteins) with 10 column
volumes (CV) of the lysis buffer followed by 2xCV of a washing buffer (20mMHEPES-NaOH pH 7.5, 2M LiCl, 5% glycerol) and further
by 2xCV of the lysis buffer, 3xCV of 5% of elution buffer (50 mMHEPES-NaOH pH 7.5, 600 mMNaCl, 2 mM b- ME, 250 mM Imidazol
and 10%glycerol) followed by 2xCV of 10%, 15%and 20%of the elution buffer. Bound proteins were elutedwith a 20xCV gradient of
20%–100% elution buffer. The Prp2 protein was then applied again onto affinity column, where tags and proteases were bound and
purified protein without the tag was collected in the flow through. Protein was concentrated using Centricon concentrators (Millipore)
and further purified by size exclusion chromatography (GE Healthcare) using buffers containing 20mMHEPES NaOH pH 7.5 and salt
concentrations ranging from 100 250 mM NaCl (depending on the protein), 2 mM DTT and 5% glycerol. The purified proteins were
analyzed by SDS-PAGE (Figure S1). Fractions with 97%or higher purity (estimated by Coomassie Blue staining) were aliquoted, flash
frozen in liquid nitrogen and stored at –80C. The concentration of the proteins was estimated by Bradford assay and A280
measurements.
HsSUV3 was purified as described in Pietras et al. (2018). Briefly, hSuv3 (47-786 aa) was expressed as N-terminal 6xHis-SUMO-
tagged protein in E. coliBL21 strain. Bacteria were cultured in autoinduction Super Broth base including trace elementsmedium (For-
medium), supplemented with 2% glycerol and kanamycin (50 mg/ml) for 48 h at 18C. Bacteria were pelleted and homogenized using
EmulsiFlex and protein extracts were subjected to purification. 6xHis-SUMO-tagged proteins purification included following steps:
Ni affinity chromatography on the 5-ml column filled with Ni-NTA Superflow resin (QIAGEN), followed by SUMO protease on-column
cleavage, desalting, a second round of Ni affinity chromatography with collection of unbound material, and gel filtration Hiload 16/60
Superdex S200 column (GE Healthcare). The purification procedure was performed using an A¨KTA express apparatus. Purified pro-
teins were analyzed by standard SDS-PAGE and Nanodrop (Thermo Fisher Scientific).
In vitro uridylation assays
With 50 32P-labeled RNA, L1-ORF1p, MOV10 and TUT4
Five pmoles synthetic RNA44 (Future Synthesis) was labeled with 32P at their 50 end in 20 mL by using 6 mL g32P ATP (10 days post the
reference date) and PNK (NEB) in 0.7x NEB2 buffer (home-made) for 30 min at 37C. The RNA was purified off unincorporated g32P
ATP by passing through SephadexG-50 column and further purified by denaturing PAGE in a 6%gel, excisedwith a single nucleotide
resolution, eluted in REB (300 mM NaOAc, 5.3; 2 mM EDTA; 0.5% phenol/chloroform/isoamyl alcohol 25:24:1) at 4C overnight and
precipitated.
Final concentrations of components in the biochemical in vitro reconstitution reactions: RNA44 0.6–1.25 nM, ATP – 0.5 mM, UTP –
0.25 mM, salt (NaCl)130 mM, DTT 1.25 mM, Tris-HCl 8.0 20 mM, MgCl2 2 mM, MOV10/HsSUV3/ScPRP25 nM, TUT40.25 nM,
cold-trap DNA oligo 30 nM. Cold trap was included to prevent rebinding of L1-ORF1p to RNA44 after it has been displaced by the
MOV10 RNPase activity.
RNA was mixed with ATP, UTP, DTT and Tris-HCl 8.0/MgCl2. 20 mL of the mix (for 4 reactions) were then mixed with 6 mL of either
500 mM NaCl/20 mM TrisTRI-HCl 8/20% glycerol or proteins MOV10, HsSUV3 or ScPRP2 suspended in this buffer. The mixes were
incubated in ice for 5 min. Thereafter 4x 6 mL from each condition were mixed with 1 mL 20 mM Tris-HCl 8/20 mM NaCl or increasing
concentrations of recombinant L1-ORF1p in this buffer (prepared as set of dilutions) to final L1-ORF1p in 10 ml: 0, 5, 10, 20 nM. The
mixeswere incubated for 5min in ice. Thereafter 2.5 mL of TUT4/cold trap DNAwere added and reactions immediately placed at 37C
in 30 s intervals. Reactions were incubated for 18min keeping the time intervals and then rapidly stopped by addition of 100 mL TNES
(Tris-HCl 8/NaCl/EDTA/SDS) supplemented with 20 ng/ml proteinase K (USB). RNA was purified by 2 rounds of phenol/chloroform/
isoamyl alcohol 25:24:1 extraction, precipitated with ethanol (after addition of 1.5 mL GlycoBlue precipitant to each sample) and
resolved in a 9.6% denaturing PAGE with single nucleotide resolution, scanned and quantified using MultiGauge software.
With 50 FAM-labeled RNA, L1-ORF1p and TUT7
FAM-labeled 44-mer RNA (RNA44, 50 nM, Future Synthesis) was combined with 0.5 mM UTP in 0.5x NEB2 buffer (home-made, 1x:
10 mM Tris-HCl pH 8, 50 mMNaCl, 10 mMMgCl2, 1 mMDTT). Recombinant L1-ORF1p (or respective buffer) was added to the indi-
cated concentration (0-150 nM) and samples were incubated 5 min at RT. Purified TUT7WT was then added to 0.5 nM and the sam-
ples were incubated at 37C for 10 min. The reactions were stopped by the addition of proteinase K (USB) in 100 mL TNES (50 mM
Tris-HCl pH 8, 100 mMNaCl, 10 mM EDTA, 1% SDS) and purified as described in ‘‘RNA isolation.’’ Finally, the RNA was dissolved in
4 mL standard formamide loading dye, loaded onto an 8% denaturing PAGE gel (20 3 20 3 0.04 cm; 28 lanes) and separated for
70 min at 700 V. The gel was immediately scanned using a FLA-9000 apparatus (GE Healthcare).
In vitro RNase I footprinting assay
Production of 32P-labeled RNA
DNA templates for in vitro RNA transcription were produced by PCR using the 99 PUR RPS EGFP plasmid as a template and forward
and reverse primers (T7_L13UTRef gtgagagatgtaatacgactcactataggGGAACTCCATATATGGGCTAT- the T7 promoter is underlined
and preceded by several stabilizing nucleotides; and L13UTRrv, TAGGGTACATGTGCACATTGC). The purified DNAwas used for two
in vitro run-off transcription reactions, ‘‘cold’’ and ‘‘hot,’’ using home-made T7 RNA polymerase to generate 79 nt RNAs. Random
32P labeling was accomplished using 0.5 mM rATP/rCTP/rGTP and 0.1 mM UTP supplemented with 0.1 mM a32P UTP that resulted
in labeling of1 of 50 transcripts. ‘‘Cold’’ and ‘‘hot’’ RNAs were separated from the template and shorter products by 6% denaturing
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illumination with UV of the gel placed on TLC with a fluorescent indicator) and the nucleic acids were eluted overnight in REB (0.3 M
sodium acetate pH 5.2, 3 mM EDTA, 1:17 vol/vol of a 25:24:1 phenol/chloroform/isoamyl mixture) followed by ethanol precipitation.
Footprinting
RNase I RNA footprintingwas performed as described in Razew et al. (2018) withmodifications. Cold and hot L1-30UTRRNA (125 nM;
final concentration in 10 mLwas 50 nMor400 cps per sample) were combined in 0.5x NEB2 buffer (home-made, 1x: 10mMTris-HCl
pH 8, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT) with 2.5 mM ATP (1 mM final concentration in 10 ml) on ice. Recombinant MOV10 or
respective buffer was then addedwhere indicated to 22 nM (15 nM final concentration in 10 ml) and samples weremoved to RT before
recombinant L1-ORF1p was added to a final concentration of 0, 20, or 100 nM in 10 ml. After 2 min, ‘‘cold trap DNA’’ (100 nM final
concentration in 10 ml) was added to all samples to bind L1-ORF1p released from the RNA byMOV10 and to prevent rebinding to the
RNA, followed by the addition of 1 mL Ambion RNase I (100 U; Thermo Fisher Scientific). The RNA was degraded with RNase I for
25 min at 25C and the reaction was stopped with 10 mL proteinase K (200 ng; USB) in TNES (50 mM Tris-HCl pH 8, 100 mM
NaCl, 10 mM EDTA, 1% SDS) and purified as described in ‘‘RNA isolation.’’ Glycoblue (2 ml) was added to the aqueous phase. So-
dium acetate (50mM, pH 5.2) was then added and themixture was precipitated for 2 h at20C. TheRNAwas centrifuged, dissolved
in 4 mL formamide loading dye and separated on an 8%PAGE gel (303 203 0.04 cm) at 1250 V for 2 h at RT. The gel was exposed to
a phosphorimager screen (Fuji) and scanned using a Fuji PhosphorImager (FLA7000).
Immunofluorescence
Preparation of cells
To visualize EGFP-tagged proteins, parental HEK293 FLP-In T-Rex cells were seeded in 6-well plates at 0.3x106 cells per well and
transfected on the following day with 2 mg pZWplasmid encoding the indicated N-terminal EGFP-tagged protein using 7 mL Lipofect-
amine 2000 (ThermoFisher Scientific) in 300 mL OPTI-MEM (GIBCO). Cell lines stably expressing the indicated proteins were also
used and treated as described below.
For co-localization studies of L1-ORF1p-FLAG and endogenous TUT7 and MOV10, HEK293 FLP-In T-Rex cells were transfected
as above but instead using 0.75 mg pZW-L1RP-O1F plasmid and 5 mL Lipofectamine 2000.
Next day cells were trypsinized and 1/5 of the cells was reseeded onto polylysine-coated glass slides in new 6-well plate wells or
33x103 cells were seeded in a single well of a 8-well Nunc Lab Tek II Chamber slides (for in vivo microscopy) in medium supple-
mented with 100 ng/ml tetracycline. Cells were analyzed 24-48h after seeding either as live cells or after fixation and staining.
Cell fixation and protein staining
To examine immunofluorescence of fixed cells, the medium was removed from the chamber and the cells were gently washed twice
with PBS at 37C. The cellular contents were fixed by overlaying 3.7% formaldehyde (from 37%aqueous solution) and 5%sucrose in
PBS at RT for 15min, after which the cells were washed with RT PBS three times. The cells were then permeabilized with 0.2% Igepal
CA-630 (NP40) with 10%FBS in PBS for 15min at RT. The permeabilized cells were washed once with RT PBS and incubated in 10%
FBS in PBS for 15 min at RT. After removing the solution, primary antibodies (see Key Resources Table) were added at 1:50 (FLAG,
TUT4, TUT7) to 1:200 (MOV10) dilutions. Monoclonal mouse anti-FLAGM2antibodies (Sigma) yielded reproducible L1-ORF1p-FLAG
staining. Monoclonal rabbit anti-FLAG antibody F2555 (Sigma) performed well after delivery and when stored at 4C, but showed no
reactivity after freezing and thawing. The cells were incubated with the antibodies for 1 h at RT, washed three times with PBS and
secondary Alexa488/555/647-coupled antibodies (depending on the staining) in 10% FBS in PBS were overlaid at 1:800 and incu-
bated for 1 h at RT. The antibodies were then removed and the cells were overlaid with 1:10,000 Hoechst in PBS for 10 min at RT to
stain DNA. The cells were washed three times with PBS and the slides were mounted using ProLong Gold Antifade (Thermo Fisher
Scientific) and left in the dark at RT to dry overnight.
Microscopic analysis
Imaging was performed using a FluoView1000 Olympus confocal system with a PLANAPO 60x/1.40 oil immersion lens. Live cell im-
aging was performed at 37C in a humidified 5% CO2 incubator. Cross-talk was tested and eliminated using bandpass filters.
Quantification of co-localization cytoplasmic foci
The foci were identified by the presence of enrichedMOV10 staining. Enrichment of plasmid-encoded TUT4 and TUT7was assessed
by merging images (confocal microscopy channels) in a single frame and visual inspection.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of LC-MS/MS data
Raw data files were used to calculate semiquantitative measures of protein abundances in the samples using MaxQuant software
version 1.3.0.5 (Cox and Mann, 2008) and default settings including DSP-acetamide modification and setting multiplicity to 1. Data-
base used for uniprot_human protein sequence database as of Feb. 2013.
Estimation of L1-ORF1p and ORF2p translation
Analysis of L1-ORF1p and L1-ORF2p translation was performed using Attune NxT software and reported in terms of EGFP and
mCherry intensities. Laser intensities accommodated the entire fluorescence range without saturation. Singlet cells were analyzed
based on initial FSC-A/SSC-A gating (gate 1) and subsequent FSC-H/FSC-A gating (gate 2 used for further analysis). Gates fore16 Cell 175, 1537–1548.e1–e17, September 6, 2018
EGFP+ and mCherry+ cells were then set according to control cells that were not fluorescent. Less than 0.02% of cells among the
control cell population were allowed within the EGFP+ or mCherry+ gates.
DATA AND SOFTWARE AVAILABILITY
The accession number for the mRNA expression data reported in this paper is GEO: GSE105264.
The primary data and output of the RACE-seq pipeline can be retrieved from http://adz.ibb.waw.pl/warkocki-et-al-2018
The scripts used in the analysis of the RACE-seq output can be found at https://github.com/smaegol/LINE_1_RACE_seq_analysis
Other data including uncropped blots, Prism files and Snap Gene files can be found at http://dx.doi.org/10.17632/zkb2nr99rw.1Cell 175, 1537–1548.e1–e17, September 6, 2018 e17
Supplemental Figures
Figure S1. Control Experiments for Plasmid-Based L1 Retrotransposition Assays, Related to Figure 1
(A) Western blotting to show expression of N’-MBP-tagged WT and MT TUT4, TUT7, MOV10 (lanes 1-5), N’-FLAG-tagged MT and WT TUT7 and MOV10 (lanes
6-8), C’-FLAG-tagged TENT4B, TENT2, TUT1 and TENT5C (lanes 9-12). Blots were probed with mouse monoclonal antibodies against MBP or rabbit polyclonal
antibodies against FLAG. A probing for g-tubulin and ponceau S staining were added as loading controls. A black arrow points to weakly expressed TENT2-FLAG
in lane 10.
(B and D) A plasmid encoding EGFP was used to test transfection efficiencies and toxicity (EGFP expression) concomitantly with co-transfection of a plasmid
overexpressing wild-type or mutant TUT4, TUT7, MOV10 or MBP (CNTRL, B) or concomitantly with siRNA-directed depletion of both TUT4/7, TUT4, TUT7,
MOV10 or non-targeting control (CNTRL, D). Data for 9 biological replicates (three independent experiments; panel B) and 3–6 biological replicates (two in-
dependent experiments, D) were normalized to controls. Means with SEM are plotted. No significant differences were observed as assessed by one-way ANOVA
and Tukey’s multiple comparison test.
(C) L1 retrotransposition assay in HEK293T cells with L1-megfpI reporters and concomitant overexpression of the indicated protein (as in panel A). Normalization
was done to TUT7 MT. Statistical significance was calculated using one-way ANOVA and Tukey’s multiple comparison test. Statistical significance of TUT7 WT
condition versus TUT7 mutant and the TENTs is shown (***p < 0.001).
(E) Western blotting to test depletion of endogenous TUT4, TUT7, both TUTases or MOV10 by siRNAs (probed with specific antibodies; probing with a-tubulin
was used as a loading control). Cells were co-transfected with the L1megfpI reporter concomitantly with siRNAs. Cells were collected on day 4 post-transfection
and split for flow-cytometry and western blotting. An asterisk marks an unspecific band detected by the anti-TUT7 antibodies (the band can be used to assess
loading). Probing with the anti-a-tubulin mouse monoclonal antibodies showed 2 bands and was not used in other blots in the paper.
(F) RT-qPCR estimation of TUT1 depletion at mRNA level by siRNAs at day 3 post-transfection (in cells co-transfected with the L1megfpI reporter). Expression
was normalized to control.
(G) Western blotting to test depletion of TUT4 and TUT7, MOV10 or both TUTases and MOV10 in HeLa-HA cells under conditions used for retrotransposition
assay with the mneoI reporter. Cells were collected at day 3 post-transfection (after co-transfection with L1-mneoI plasmids).
Data on panels C and F are presented as medians with individual points and interquartile ranges shown.
The western blotting exposures were done either to a film and scanned by an Epson scanner and bottom scanning option (panel G) or by a CCD camera (panels A
and E). The singnals in the images acuired with a CCD camera were digitally enhanced by using ‘adjust levels’ option for the entire images.
(legend on next page)
Figure S2. 30 RACE-Seq of Endogenous and Reporter L1 mRNAs and of Control Cellular mRNAs, Related to Figure 2
(A) Distribution of U-tails, AU-tails and A-tails in endogenous L1, ACTB, GAPDH, PABPC4 and SOGA2mRNAs (as indicated) possessing non-templated 30 end
nucleotides in the indicated cells/organs: PA-1 cells, human embryonic stem cells (H9), human neuronal progenitor cells (NPC) and in mouse testes (MT). The
fraction of transcript 30 ends is shown in the y axis with total set to 100%. Tails were binned in 10-nucleotide bins (but 1-9 and 60+) according to their length and
are visualized in x axis. A black dashed line overlaid onto the graphs and represents total tail-length distribution, normalized to 100% and shown as % of total
transcripts (y axis).
(B) Distribution of 30 tails in endogenous L1 mRNAs in PA-1 cells transfected with control non-targeting siRNA (CNTRL) or siRNAs against MOV10 or TUT4 and
TUT7. The tails were assigned to one of four classes: U-tail (mono- and oligouridylated, but not adenylated); AU-tail (adenylated and mono- and oligouridylated);
‘‘no tail’’ (neither adenylated nor uridylated, mostly truncated within the 30 UTR); A-tail (oligo- and polyadenylated).
(C) Uridylation of control mRNAs: ACTB, GAPDH and PABPC4 (as indicated) in PA-1 cells transfected with control non-targeting siRNA (CNTRL) or siRNAs
against MOV10 or TUT4 and TUT7. Statistical significance was calculated using one-way ANOVA and Tukey’s multiple comparison test significance (***p <
0.001). No statistical significance was reported between CNTRL and MOV10 depletion.
(D) Distribution of U-tail lengths in reporter L1 mRNAs in HEK293 cells under overexpression of the indicated proteins. The U-tails were grouped according to the
number of uridines. Data were normalized to all mRNAs for a given condition.
(E) Examples of 30 RACE clones with reporter L1 mRNAs, to show the presence of oligouridylated (1,2) and oligoadenylated and oligouridylated 30 ends (3).
Dashed lined boxes indicate the presence of non-templated nucleotides. Blue background indicates 50 end of the 30 adaptor used (different for 1, 2 and 3).
(F) Uridylation of control mRNAs: ACTB,GAPDH, PABPC4 and SOGA2 (as indicated) in HEK293 cells overexpressing MBP (CNTRL), wild-type or mutant TUT4/7
and MOV10. Statistical tests were performed as in panel C. No statistically significant changes were observed.
(G) Uridylation of control mRNAs: ACTB, GAPDH, PABPC4 and SOGA2 (as indicated) in HEK293 cells depleted of TUT4 and TUT7 or TUT1 (as indicated).
Statistical significance was calculated as in panel C and is shown where applicable.
(H) Distribution of U-tail lengths on reporter L1 mRNAs in HEK293 cells under depletion of the indicated proteins. The U-tails were grouped according to the
number of uridines. Data were normalized to all mRNAs for a given condition.
(I) Uridylation of L1 reporter mRNAs in control HEK293 cells (transfected with non-targeting siRNAs, CNTRL) and in cells depleted of TUT1.
Data on panels C, F, G, and I are represented as medians with individual points and interquartile ranges shown.
Figure S3. 30 RACE-Seq and LEAP Products Sequencing of the L1 Reporters with Defined 30 Ends, Related to Figure 3
(A) Graphs showing distribution of total tails’ lengths in 30 RACE-seq data of L1 reporters designed to possess at their 30 ends either of: 26A, 26A2U, 26A4U,
26A6U or 26A14U. The respective reporters are color coded as indicated.
(B) Logos representing the 30 RACE-seq data for the indicated reporters. Shown is the CGGC sequence common to all reporters and specific sequences.
Probability of a given nucleotide and of the position occupancy in general is calculated in bits and depicted accordingly.
(legend continued on next page)
(C) Plasmids (24), whose inserts’ sequencing is shown in panel D, were cut with XbaI and XhoI Fast digest restriction enzymes, yielding fragments of expected
length (approximately 130bp). Lanes from left to right correspond to clones 1-24 in the table in panel D. A molecular weight ladder was included, with the two
fastest migrating bands corresponding to 100 and 200bp, respectively.
(D) Validation of genuine reverse transcription of uridylated L1 mRNAs by L1-ORF2p. LEAP products seen in Figure 3D lane 5 were cloned into pJET 1.2 blunt
plasmid, and single bacterial colonies used for preparation of plasmids. Clones were sequenced and the results are summarized in the table. One clone (10)
possessed a chimeric sequence comprising a short stretch of the L1 reporter plasmid-encoded sequence (in italics) followed by the genuine 30 LEAP adaptor
sequence. 3 clones had a heterogenous sequence cloned (2, 20 and 24), while clone 6 had the expected L1 30end followed by a 0.7Kb long sequence of unknown
origin.
(legend on next page)
Figure S4. Effects of TUT4/7 and MOV10 on L1 mRNA Steady-State Levels, Stability, and Translational Competence, Related to Figure 4
(A) Northern blotting to detect endogenous L1 mRNAs in HEK293 (FLP-IN T-Rex), HEK293T, PA-1 and HeLa-HA cells as indicated. Total RNA (lanes 1-4), un-
bound RNA fraction retrieved after selecting for poly(A) (SN, using PolyA Purist MAG from Ambion; lanes 5-8) and poly(A) RNA (lanes 10-13). The amount of RNA
loaded is indicated (mg). The same blot was re-probed forGAPDH and stained with methylene blue prior to any probing, and results are shown below (i.e., loading
controls). Substantial fraction of unbound L1 mRNAs likely represents oligouridylated or truncated mRNAs.
(B) Confocal microscopy pictures (maximal projections in z) showing mostly cytoplasmic localization of L1-ORF1p-FLAG (stained with rabbit anti-Flag mono-
clonal antibodies and secondary Alexa 488 coupled antibodies) and of endogenous TUT4 and MOV10 proteins.
(C) Rapid cell fractionation following the protocol described by Suzuki et al. (2010) and subsequent western blotting to assess subcellular localization of TUT7,
TUT4, MOV10 in PA-1 cells. Blotting for cytoplasmic (g-tubulin) and nuclear (histone H4) markers were also performed. W – whole cell, C – cytoplasmic
compartment, N – nuclei. An asterisk denotes an unspecific band.
(D) Western blot analysis of proteins in PA-1 cells after siRNA-mediated depletion of TUT4 and TUT7 or MOV10, as indicated at the top of the panel. CNTRL
denotes non-targeting siRNAs. A total of 30% (2x) and 5% of the control sample were loaded as indicated at the top, to assess depletion efficiency. Blots were
probed with rabbit polyclonal antibodies as indicated on the left. GAPDH was used as a loading control. Superfluous lanes irrelevant to the study were removed
(indicated with the black line).
(E) Western blot validation of overexpression (upper panel) and knock-down (lower panel) in HEK293 (FLP-IN T-Rex) cells used for RNA-seq experiments to
analyze endogenous L1 mRNA steady-state levels. Cells (triplicates) were split for RNA isolation and western blots. Blots were probed with rabbit polyclonal
antibodies for the detection of MOV10, TUT7, TUT4, GAPDH and actin. The latter two proteins were used as loading controls. Different volumes of lysates were
loaded to help assess overexpression and depletion efficiencies. Samples and loading volumes are indicated.
(F) RNA-seq-based estimation of endogenous L1 expression in PA-1 cells transiently depleted of TUT4 and TUT7, MOV10 or all three proteins as indicated, using
siRNAs (see panel D). Uniquely mapped reads for 76Homo sapiens-specific L1s were calculated and normalized to respective controls as indicated. None of the
observed changes is statistically significant.
(G–I) Estimation of endogenous L1-Ta mRNAs by RT-qPCR using probes as described in Coufal et al. (2009), in PA-1 (G), and HEK293 FLP-IN T-Rex stable cell
lines (in which indicated proteins were overexpressed by addition of tetracycline, and normalized to cells without tetracycline; H) or in HEK293 FLP-In T-Rex cells
depleted of the indicated protein/s (I). Three to six biological replicates including those used in the RNA-seq were analyzed.
(J) Plasmid JM101/L1.3-O1EGFP-O2mcherry contains a full-length L1 L1.3 (Sassaman et al., 1997) element producing L1-ORF1p-EGFP and L1-ORF2p-
mCherry. Additionally, the plasmid contains the mneoI cassette (Moran et al., 1996) to monitor retrotransposition.
(K) A retrotransposition test with the JM101/L1.3-O1EGFP-O2mcherry and parental JM101/L1.3. Addition of both fluorescent proteins in L1 ORFs does not
severely compromise its retrotransposition potential.
(L and M) HEK293T cells were co-transfected with JM101/L1.3-O1EGFP-O2mcherry and plasmids overexpressing the indicated TUTases or MOV10. The
percentage of cells expressing L1-ORF1p-EGFP (L) and L1-ORF2p-mCherry (M) were estimated in the total cell populations using FC. Normalized values from
8 biological replicates (3 independent experiments) are shown. Statistical significances were calculated using one-way ANOVA and Tukey’s multiple comparison
test (***p < 0.001, **p < 0.01, comparison to MBP).
(N) Plasmids of the pZW-L1RP series containing a full-length L1 (L1RP, Kimberland et al., 1999) element in a modified pcDNA5 FRT/TO backbone producing
L1-ORF1p and L1-ORF2p with either an epitope FLAG tag or fluorescent EGFP or mCherry tags as indicated. All but pZW-L1RP-O2G were produced without or
with the megfpI L1 retrotransposition reporter cassette.
(O) Retrotransposition test with pZW-L1RP-O1F-megfpI and pZW-L1RP-O1mCh-megfpI reporters. The presence of either tag does not prevent L1
retrotransposition.
(P) Translation of L1-ORF1p-mCherry encoded in pZW-L1RP-O1mCh plasmid. Cells expressing mCherry over background levels (HEK293T cells transfected
with control L1 plasmid not encoding any fluorescent tag) were considered. Median mCherry intensity was calculated and used as a measure of L1-ORF1p-
mCherry translation.
(R) Translation of L1-ORF2p-EGFP encoded on the pZW-L1RP-O2G plasmid was estimated as in (P) except for EGFP. Six to nine biological replicates (2 or 3
independent experiments) were analyzed.
Statistical significances in (P) and (R) were calculated as in panel (L).
Data on panels G, H, I, L, M, O, P, and R are presented as medians with individual points and interquartile ranges shown.
The western blotting exposures were done either to a film and scanned by an Epson scanner and bottom scanning option (panels C and D) or by a CCD camera
(panel E). The singnals in the images acuired with a CCD camera were digitally enhanced by using ‘adjust levels’ option for the entire images.
Figure S5. Stable Cell Line Validation and Co-IP Experiments, Related to Figure 5
(A) Flow cytometry profiles of parental HEK293 FLP-IN T-Rex (black traces) and stable cell lines expressing EGFP-TUT4 or EGFP-TUT7 in the absence of (blue
traces) or following induction of transgene expression with 100 ng/ml tetracycline (green traces). ‘‘EGFP+ GATE’’ denotes the region with cells showing higher
EGFP fluorescence than 99.9% of the control cells that do not express EGFP. The histograms were obtained using Flowing software. The table below the
histograms summarizes the percentage of EGFP+ cells within each experimental population.
(B) Western blot validation of the EGFP-TUT4-expressing stable cell line. Cells were grown for 48 h without tetracycline or with addition of 25, 50 or 100 ng/ml
tetracycline in the medium. Proteins were separated by SDS-PAGE, followed by transfer to nitrocellulose membranes and Ponceau S staining (lower panel) to
control for protein loading. The upper panel shows results after probing with a TUT4-specific rabbit polyclonal antibody.
(C) Western blot validation of the EGFP-TUT7-expressing stable cell line as in (B). Lanes 1 and 5 are reference lanes with material from the EGFP-TUT4 cell line
and parental HEK293 FLP-IN T-Rex cells, respectively, to show antibody specificity. An asterisk denotes an unspecific band.
(D) HEK293 FLP-In T-Rex cells were fixed with formaldehyde and stained for endogenous TUT4 (upper panel) or TUT7 (lower panel) with rabbit polyclonal
antibodies and Alexa 488-coupled secondary goat anti-rabbit antibodies. Nuclei were visualized by Hoechst DNA staining (cyan). Maximal projection images of
z stacks are shown. White bars, 10 mm
(E) Single z-slides (epifluorescent – left, and bright field – right) of live cells from stable cell lines expressing either EGFP-TUT4 (upper panel) or EGFP-TUT7 (lower
panel). White bars, 10 mm
(F and G) Rapid cell fractionation following the protocol described by Suzuki et al. (2010) and subsequent western blotting to independently assess subcellular
localization of TUT7, TUT4, MOV10. Blotting for cytoplasmic (tubulins or GAPDH) and nuclear (fibrillarin, RRP6 nuclear exosome complex exoribonuclease)
markers were also performed. Cells were either parental HEK293 FLP-IN T-Rex (F), or HeLa-HA used in L1 mneoI reporter assays (G). An asterisk denotes an
unspecific band.
(H) Western blotting of proteins associated with either EGFP-MOV10 or EGFP showed are: blot for TUT7 probing (left), probing with monoclonal aEGFP antibody
(middle; 1% co-IP), and polyclonal anti-TUT7 antibodies (right, 5% co-IP, blot before probing depicted on the left). Visible is TUT7 in EGFP-MOV10 co-IP and not
in control EGFP co-IP. In TUT7-probed blot some cross-reactivity toward overrepresented EGFP-MOV10 but not EGFP can also be seen.
(legend continued on next page)
(I) Flow-chart of the workflow of the RNA co-IP with FLAG-TUT7.
(J) western blotting showing efficient depletion of MOV10 in HEK293T cells used for in vivo UV-crosslinking and co-IP with FLAG-TUT7. Shown are western
blotting results after probing with polyclonal antibodies against MOV10 and GAPDH (loading control). Cells were transfected with: Lane 1 – control non-targeting
siRNA then plasmids encoding L1 reporter andMBP-TUT7; lane 2 –MOV10 targeting siRNA then plasmids encoding L1 reporter and FLAG-TUT7; lane 3 – control
non-targeting siRNA then plasmids encoding L1 reporter and FLAG-TUT7; lanes 4 and 5 – as in lane 3 but 0.5 and 0.2 of the material seen in lane 3 was loaded
(control to compare with lane 2).
(K) SDS-PAGE and silver staining of proteins recovered in the MBP- and FLAG-TUT7 co-IP after in vivo UV-crosslinking. Visible are bands representing FLAG-
TUT7 (lanes 2 and 3, indicated with an asterisk) andM2 antibody stripped off the beads (lanes 2-4). Loadedwere ca. 10% recoveredmaterial (lanes 2, 4) and6%
recovered material (lane 3). Lane 1 – molecular weight ladder (170 and 55 kDa bands are indicated); lane 2 – IP with MBP-TUT7 (control); lane 3 – IP with FLAG-
TUT7 from MOV10-depleted cells; lane 4 – IP with FLAG-TUT7 from control cells.
The western blotting exposures were done either to a film and scanned by an Epson scanner and either top or bottom scanning options (panels B and F
respectively) or by a CCD camera (C, G, H, J panels). The signals in the C, G, H and J panels were digitally enhanced by using ‘adjust levels’ option for the entire
images (but for the middle H panel).
Figure S6. MOV10 Prevents Binding of L1-ORF1p to L1-RNA, Related to Figure 6
(A) A 50-FAM-labeled RNA was incubated with increasing amounts of recombinant L1-ORF1p in the presence of TUT7 WT purified from human cells and UTP
(lanes 2-6). A reaction containing only the RNA (lane 1) was included as a control. Another reaction containing the RNA, UTP andWT TUT7 but no L1-ORF1p was
also included (lane 2). On lanes 3-6, increasing amounts of recombinant L1-ORF1p were added (as indicated at the top), changing themolar ratio of L1-ORF1p to
the RNA from 0 to 3-fold. Reactions were stopped, purified and separated by PAGE.
(B) Quantification of the RNA present in the reactions shown in panel (A). Note that the graph contains the results of three independent experiments. Measured
values were corrected for background, assuming no elongation in the control samples. Medians, ranges and individual points are shown. Statistical significances
were calculated using one-way ANOVA and Tukey’s multiple comparison test (***p < 0.001, **p < 0.01).
(C) RNase I footprinting assay. An in vitro transcribed L1-30UTR RNAwas labeled randomly by the incorporation of a32P UTP and incubated alone (lane 2), or was
incubated in the presence of Mg2+ATP (lanes 3-8), without (lanes 3 and 6) or with recombinant L1-ORF1p in the indicatedmolar ratio to RNA (lanes 4, 5 and 7, 8) or
with MOV10 purified from human cells (lanes 6-8). Note that MOV10 was added prior to L1-ORF1p addition. Lanes 1 and 9, alkaline hydrolysis ladders used as
RNA mobility makers. An arrow points to full length L1 RNA.
(D) RNase I footprinting assay as in panel C. The in vitro transcribed L1-30UTR RNA (lane 1) was incubated in a buffer supplemented with Mg2+ and with ATP and
increasing concentrations of L1-ORF1p (lanes 2-4); followed by incubation with MOV10 (lanes 5-7); or preceded by incubation with MOV10 (lanes 8-10); or
preceded by incubation with MOV10 but without ATP (lanes 11-13). Finally, all the samples (excluding lane 1) were depleted of Mg2+, subjected to RNase I
footprinting, purified and separated by denaturing PAGE. Visible is lack of L1-ORF1p displacement in lanes 12 and 13 as compared to lanes 9 and 10. Visible is
effect of MOV10 addition after L1-ORF1p in lanes 6 and 7 that might suggest kinetic competition of MOV10 and L1-ORF1p in binding to RNA. The arrow points to
full length L1 RNA.
(E) RNase I footprinting assay as in panel C but with either wild-type (lanes 2-4) or mutant (K530A) MOV10 (lanes 5-7). Visible is increased protection of the RNA in
mutant MOV10 condition, which suggests less effective competition/removal of L1-ORF1p of the RNA by the mutant protein. The arrow points to full length
L1 RNA.
Figure S7. Graphical Visualization of the 30 RACE-Seq Approach, Related to Figure 2
(A) Graphical representation of 30 RACE-seq library preparation and the oligonucleotides used. First, the 30 adaptor RA3_15N was joined to the 30 end of RNA by
enzymatic ligation. The adaptor has: (i) 50 rAppmodification for efficient and specific ligation by the truncated T4 RNA ligase 2, (ii) delimiter sequence to be used in
bioinformatics analyses to exclude RT and PCR artifacts (CTGAC, highlighted in violet), (iii) unique 15N barcode for individual transcript barcoding (highlighted in
green), (iv) anchor sequence to pair with the reverse transcription primer (underlined) and (v) dideoxyC on the 30 end to prevent concatamer formation. The RNA
ligated to the adaptor sequence was purified from excess adaptor and reverse transcription was performed with the RT primer, which is compatible with Illumina
sequencing and has: (i) sequences to base-pair with the adaptor (underlined), (ii) 6-nucleotide barcode for sample barcoding (highlighted in red), (iii) sequences
that base pair with the universal outer primer for nested PCR (blue).
(legend continued on next page)
Libraries were generated by nested PCRwith 2 outer forward primers (F1 and F2) and a single universal reverse primer (uni rev). PCR amplicons of first and second
PCRs were purified from excess primers on AmPure beads (Agencourt) before beginning the next step.
(B) Flowchart of the bioinformatics approach to 30 RACE-seq data analysis. The procedure starts at the top. Datasets are shown in rectangles. Software used is
depicted in hexagons.
